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ACE inhibition (ACE!) versus p-blockade in antihypertensive therapy
of diabetic (type !) nephropathy. C. Gronhagen-Riska, E. Honkanen, K.
MetsOrinne, K. Rosen/of, IVth Department of Medicine, University of
Helsinki, Finland. Claims of superior renal protective and antiproteinu-
nc effects of ACE inhibitors compared with other anti-hypertensive
drugs should be tested in controlled long-term human studies. We
randomized 33 IDDM patients with overt nephropathy to compare
enalapril (Ena) with atenolol (Ate). Twenty patients (10 + 10) have
completed 12 months. Furosemide (8 Ate, 8 Ena) and nifedipine (4 and
3) were added to achieve target dRR 90 mm Hg.
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Mean values indicate similar MAP reductions, but superior, long-term
antiproteinuric effect of Ena. Protein excretion and MAP changes did
not correlate. So far, no difference in rate of decline has been observed.
In spite of improved SAIb, SchO levels did not differ between groups.
There have been 7 + 8 drop-outs within 12 months, in Ate group mostly
due to inadequate pressure reduction, and in ENA group due to drug
specific side-effects such as cough and hyperpotassemia.
A randomized controlled trial of the effect of enalapril on the progres-
sion of chronic renal failure. AL. Kamper, S. Strandgaard, PP.
Leyssac, Departments of Nephrology and Clinical Physiology, Herlev
Hospital and institute of Experimental Medicine, The Panum institute,
Copenhagen, Denmark. To study the influence of angiotensin convert-
ing enzyme (ACE) inhibition on progression of chronic nephropathy, 70
patients with a median glomerular filtration rate (GFR) of 15 (range, 6 to
54) ml/minll .73 m2 were randomized in an open study to basic treatment
with enalapnl or conventional antihypertensive treatment. The patients
were followed for at least 2 years or until need for dialysis. The groups
were comparable with respect to age and sex distribution, etiology of
renal diseases, initial levels of renal function, the presence of hyper-
tension, protein intake (which was fixed during the study). The thera-
peutic goal was an arterial blood pressure (BP) of 120 to 140/80 to 90 mm
Hg. GFR, estimated by the plasma clearance of 51Cr-EDTA, was
measured every third month, and the individual rate of progression was
calculated as the slope of the GFR versus time plot. In the enalapril
group, the median decline in GFR was 0.20 (range, —0.18 to —7.11)
mllmin/1.73 m2 per month, and in the control group it was 0.31 (—0.01
to —1.97) mI/min/! .73 m2 per month (P < 0.05). There was no significant
difference in BP or plasma lipid levels between the groups. Thus, the
progression of moderate to severe chronic nephropathy was slowed by
treatment with enalapril. This effect was independent of the systemic
antihypertensive effect.
Enalapril gives long-standing reduction of proteinuria in patients with
chronic nephropathy, but the effect may be reversible after discontinu-
ance of treatment. T. Linné, Department of Pediatrics, Karolinska
Institute, St. Goran's Hospital, Stockholm, Sweden. Short- and long-
term effects from angiotensin converting enzyme inhibition (ACE!) with
enalapril on proteinuria, blood pressure and renal function were studied
in eight patients (age 14.2 5.5 years, range 5.8 to 20.9) with chronic
nephropathy and proteinuria. The duration of disease was 8.0 5.6
years. GFR was reduced in three patients (<90 ml/min/l.73 m2; range
69 to 79). After 1 to 1.8 years, the ACE! treatment was discontinued for
one month in order to evaluate to what extent the effects were
persistent. After I to 4 months of ACEI treatment the proteinuria was
invariably lower than before (0.6 0.4 g/24 hr, range 0.1 to 1.2, vs. 0.3
0.3, range 0 to 0.9; P < 0.05), an effect which remained after 12
months (0.2 0.4). C1,, CPAH and FF were unchanged after 12 months
of enalapril treatment, while the BSA-related albumin excretion was
significantly lower than before the treatment started. The mean arterial
pressure decreased during the first months of treatment in 7/S patients
(89.3 9.6 mm Hg vs. 82.5 11.2; NS). Discontinuance of ACE!
treatment was followed by increased 24-hour protein excretion in 7/S
patients (0.4 0.8 vs. 0.7 1.0 g/24 hr; P < 0.05) and urine
albumin/creatinine quotient in 8/8 (P < 0.05). ACE! thus gives early and
long-standing reduction of proteinuria. The effect, however, may be
reversible after discontinuance of treatment. Whether ACEI treatment
will improve the long-term prognosis has yet to be proven.
The morphological basis for progression of chronic renal diseases. N,
Marcussen and T. Steen Olsen, University Institute of Pathology,
Arhus Kommunehospital, Arhus, Denmark. In primary glomerular
diseases, the advancing obsolescence of glomeruli is generally held to
be responsible for progression towards end-stage renal disease (ESRD).
This explanation cannot be sustained for nonglomerular diseases where
glomeruli are often without significant lesions; and even in glomerular
diseases, the lack of correlation between glomerular lesions and GFR
indicates that other mechanisms must be operative. There is, however,
in all types of chronic renal diseases a close inverse relationship
between GFR and tubulointerstitial lesions. Impressed by this apparent
paradox, we have studied the glomerular changes and the connection
between glomeruli and tubules in further detail. Using serial sections
and morphonietry in both animal models (nephropathy due to lithium
and cisplatin) as well as human chronic pyelonephritis and renal artery
stenosis, we have documented the presence of a significant proportion
of glomeruli without connection to proximal tubules (atubular glomer-
uli). A close relationship was found between this lesion and renal
function. We will discuss this new aspect within the framework of
current hypothesis for progression of chronic renal failure towards
ESRD.
© 1992 by the International Society of Nephrology
Dyslipoproteinemia accelerates progression of renal insufficiency. 0.
Samuelsson, P. Alaupovic, and P-0 Auman, Department of Nephrol-
ogy, Sahlgrenska sjukhuset, University of Goteborg, Sweden, and
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Lipoprotein and Atherosclerosis Research Program, Oklahoma City,
Oklahoma, USA. To investigate whether the dyslipoproteinemia seen
in human renal insufficiency also influences the development of renal
failure, we have prospectively related the plasma levels of lipids and
apolipoproteins to the change in renal function in 34 adult patients with
chronic renal disease. Progression was measured as the change in GFR
over time. The patients were followed with repeated GFR determina-
tions for an average of 26.7 12.7 months (range 6—60 months). The
mean initial GFR was 34.6 14.3 ml/min/l.73 m2 BSA. The rate of
progression was characterized with regard to the rate of decline in GFR
(—AGFR ml/min/l.73 m2 BSA per month) as stable (—AGFR 0.10; N
= 9), slow (—zGFR = 0.11—0,30; N = 12) or rapid (—GFR > 0.30; N
= 13). The mean initial GFR did not differ between these three patient
groups. The Table gives the initial lipid profile in these patients:
Stable
(N = 9)
Slow
(N = 12)
Rapid(N = 13)
Blood pressure mm Hg 134/84 139/84 146/84
Triglycerides mmol/liter 1.44 1.32 2.09
Cholesterol mmol/liter 4.73 6. l9 5 90
LDL-Cholesterol 2.77 4.13a 339
mmol/liter
Apolipoprotein A-I mg% 108 116 112
Apolipoprotein B mg% 87 1 19 129
Apolipoprotein C-Ill 16.8 15.2 17.1
Apolipoprotein A-I/C-Ill 7.4 8.1 8.0
Diabetes mellitus 4 4 7
(no. of pts)
P < 0.05, compared to Stable group
Conclusion: These data suggest that lipoprotein abnormalities influence
the course of chronic renal disease. Higher cholesterol levels, LDL-
cholesterol levels and specifically higher apolipoprotein B levels are
associated with progression of renal insufficiency in human renal
disease. Thus, patients developing progressive renal insufficiency ex-
hibit a lipoprotein profile qualitatively similar to that seen in accelerated
atherosclerosis.
Contrast media as GFR markers in clinical routine. M. Aurell and R.
Volkmann, Departments of Nephrology and Clinical Physiology, Sahi-
grenska Sjukhuset, University of Gäteborg, GOteborg, Sweden. Ade-
quate GFR measurements in clinical routine are gaining increasing
importance in many kidney disorders. Contrast media, long since
recognized as GFR markers by their clinical use, have been limited for
methodological reasons, such as isotope labelling of the substances. A
new roentgen-fluorescence technique allowing the precise measurement
of contrast media concentrations in plasma and urine has brought new
interest to contrast media as GFR markers. Among newer contrast
media, iohexol, a low osmolar non-ionic substance, has been claimed to
be suitable for GFR measurements. In 71 patients we compared GFR
measurements using both the 51Cr-EDTA and iohexol clearances.
Plasma clearance for CrEDTA and iohexol were determined simulta-
neously according to BrØchner-Mortensen in the time interval of
150—240 mm after the injection. A total of 1.8—3.8 MBcq CrEDTA and
20 ml iohexol (300 mg/mI) were administered, and plasma concentration
of CrEDTA measured with a scintillation counter and iohexol with the
Renalyser PRX 90 (Provalid AB, Sweden). In 24 patients with GFR <40
mI/mm/I .73 m2 the renal clearances of both substances after single-
injection were determined using urine sampling for three periods of 40
mm each. The bladder was emptied by spontaneous voiding. The
correlation between the 51CrEDTA and iohexol clearances in the
clearance interval of 40—180 mI/mm/I .73 m2 was significant and close to
unity (r = 0.85). The correlation between renal 51Cr-EDTA clearance
and the lohexol plasma clearance in the clearance interval >30 ml/min/
1.73 m2 was less good, albeit significant (r = 0.72). The correlation
between renal clearances for CrEDTA and iohexol was very good (r =
0.91). We conclude that plasma iohexol clearance may be an adequate
substitute for CrEDTA plasma clearance in patients with GFR >30
mI/mm/I .73 m2 and the renal iohexol clearance in patients with GFR
<30 mI/mm/i .73 m2. The new roentgen-fluorescence method of mea-
suring contrast media in plasma and urine is a great step forward to
increase the availability of adequate GFR measurements in clinical
routine.
lopentol in patients with renal failure. K.J. Berg, F. Kolmannskog,
P.E. Lillevold, K.P. Nordal, K. Roorwelt, L. Ressem, and M. Svaland,
Departments of Medicine B, Diagnostic Radiology and Clinical Chem-
istry, Rikshospitalet, Oslo, and Nycomed AIS, Research and Develop-
ment Division, Oslo, Norway. The non-ionic contrast medium (CM)
iopentol was administered for abdominal angiography and pelvic aor-
tography in 10 patients with advanced renal failure (GFR 9.3 7.6
mi/mm). The elimination half life of iopentol was increased from 2 to
28.5 hours, the fecal excretion was up to ten times higher, whereas the
distribution volume was unchanged as compared to healthy controls.
GFR parameters (plasma mTcDTPA and creatinine clearances) were
unchanged by iopentol, as was the urinary excretion of N-acetyl-13-
glucosaminidase (NAG) and alkaline phosphatase (ALP). GFR was
overestimated by 47% with creatinine clearance and by 40% with
plasma iopentol clearance compared to renal iopentol clearance, the
difference being most pronounced in the patients with the lowest GFR.
Plasma 99mTcDTPA clearance was even less reliable as a GFR para-
meter. We conclude that abdominal aortography with the non-ionic CM
iopentol could be performed without side effects in patients with
advanced renal failure. If CM is used for measurement of GFR in this
group of patients, the renal clearance of the CM should be measured.
Contrast medium as a marker of GFR in patients with impaired renal
function. B.G. Danielson, T. Salmonson and B. WikstrOm, Renal
Section, Department of Medicine and Medical Products Agency,
Uppsala, Sweden. In many renal patients there is need of an accurate
evaluation of glomerular filtration and to monitor renal function over
long time periods. The gold standard has been inulin clearance deter-
minations. Due to high costs and inconvenience, this method cannot be
routinely used in clinical practice. 51Cr-EDTA has similar drawbacks.
The use of x-ray contrast media, e.g. iohexol, as a glomerular filtration
marker has been proposed for this purpose. However, these substances
are known to be nephrotoxic, particularly in large doses. In the present
study, the plasma clearance and the renal clearance of iohexol were
investigated in healthy volunteers and in patients with impaired renal
function. To study the possible influence of iohexol on tubular function,
several indicators of tubular damage were assayed in urine before and
after the injection of the contrast medium. Different methods of
calculation of clearance were compared in order to give possible
recommendations of dosage and calculation procedure in patients with
various degrees of renal failure.
Evidence for internalization and accumulation of radiographic contrast
media in kidney tubular cells of the male rat. A. Nordby, K.E. Tvedt, J.
Halgunset, and O.A. Haugen, Department of Radiology, Department
of Pathology, and Institute of Cancer Research, University of Trond-
heim, Trondheim, Norway. Radiographic iodine-containing contrast
media (meglumine calcium metrizoate, iohexol and meglumine sodium
ioxaglate) were injected intravenously in rats. At various intervals after
exposure the rats were anaesthesized, and an abdominal incision was
made. The kidneys were freed from the posterior abdominal wall, and
cryofixation was performed without prior interruption of the circula-
tion. Thin, freeze-dried cryosections were examined by electron mi-
croscopy and X-ray microanalysis. In endothelial cells, erythrocytes
and tubular cells high dry weight concentrations of iodine were found.
Twenty-four hours after iohexol was injected, no trace of iodine was
found in the plasma, microvilli or the nuclei of the tubular cells. Small
organelle-like compartments in the cytoplasm of the proximal tubular
cells contained high concentrations of iodine, whereas no iodine was
found in the surrounding cytoplasm. Since no metabolism of contrast
medium has been demonstrated, the iodine signals must be emitted
from contrast medium molecules. Other elements were also measured,
and the concentrations were always within the ranges found in tubular
cells of control animals. The detection of intracellular contrast thus
does not seem to be an artifact due to cell injury, but rather represents
a physiological event in healthy cells in the rat kidney. Our results are
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in contradiction to the prevailing opinion that contrast media do not
enter healthy cells. However, previous conclusions have been based on
the use of conventional preparation methods, and the highly water
soluble contrast molecules may have been lost during the different steps
of fixation and processing.
Metabolism of parathyroid hormone in uremia. Studies with isolated
perfused livers and kidneys from normal and uremie rats. H. Dan gaard,
M. Egfjord, and K. Ølgaard, Medical Department P, Division of
Nephrology, and Department of Experimental Pathology, Rigshospi-
talet, University Hospital, Copenhagen, Denmark. The uremic state is
accompanied by elevated levels of both intact parathyroid hormone
(PTH) and fragments of the hormone. In uremia, the peripheral metab-
olism of secreted intact PTH has been shown to be the main source of
PTH fragments in plasma. Several in vitro studies have shown that
these fragments may act as uremic toxins, and physico-chemical PTH
fragments are 'mid-molecules'. We therefore investigated the metabo-
lism of biologically-active synthetic human intact PTH at high and
normal physiological concentrations in isolated perfused livers, and in
filtering and non-filtering kidneys, from uremic and normal rats. Meta-
bolic clearances were measured by an assay specific for intact PTH and
assays highly specific for NH2-terminal or COOH-terminal immunore-
active PTH (iPTH). The PTH fragments generated by the metabolism of
intact PTH in the perfused organs were characterized by extensive
high-performance liquid chromatography (HPLC) studies. The clear-
ance of intact PTH in the livers from uremic rats was not significantly
different from the clearance in the livers from the normal controls. The
HPLC studies demonstrated generation of mainly COOH-terminal
fragments. Several COOH-terminal subfragments were generated with-
out any consistent pattern, and no differences could be demonstrated
between the fragments generated by uremic versus normal livers. The
rats in these studies were made uremic by 5/6 nephrectomy, and it
proved possible to perfuse the remnant left 1/3 kidneys. Filtration!
metabolism of intact PTH was significantly (P < 0.01) lower in the
uremic kidneys. The difference was not significant, however, when the
total PTH clearance was corrected for the lower glomerular filtration
rate in the uremic kidneys. Thus, the accumulation of intact PTH and
COOH-terminal PTH fragments in uremia may be due mainly to the
reduced GFR.
Calcium acetate as phosphate binding therapy in chronic renal failure.
B. WikstOm, B.G. Danielson, and B. FellstrOm, Department of Medi-
cine, University Hospital, Uppsala, Sweden. Toxicity of aluminium
gels for phosphate binding has focused the interest on using aluminium-
free alternatives for control of serum phosphate. Various calcium salts
have been used as such alternatives. However, insufficient effect
(calcium citrate) or side effects such as frequent hypercalcemia (calcium
carbonate) have limited the use of calcium salts. From a theoretical
standpoint calcium acetate (high relative calcium content, pH-indepen-
dent solubility) could act as an efficient phosphate binder. In this study,
30 patients (mean age 54 years) with uremic hyperphosphatemia were
treated with calcium acetate (Phos-Ex) during 6 months. The patients
were transferred from treatment with aluminium hydroxide or/and
calcium carbonate to calcium acetate in doses of 330—2000 mg daily
together with meals. Doses were adjusted aiming at a serum phosphate
level <2 mmol/liter. Results and conclusion. The serum phosphate
levels could be kept around 2 mmollliter. Mean levels of serum calcium,
alkaline phosphatases and PTH did not change during the study.
However, serum aluminium decreased significantly. Six episodes of
moderate hypercalcemia (>2.8 mmol/liter) occurred in six patients
without necessitating withdrawal of treatment. In two patients calcium
acetate was withdrawn due to gastrointestinal discomfort. Thus, ac-
ceptable control of serum phosphate with relatively few side effects can
be achieved with calcium acetate.
Experience of acute and chronic vascular access in renal failure. A .A.
Alarabi, B. WikstrOm, B.G. Danielson, J. Wahlberg, and G. Tufvesson,
Departments of Medicine and Urology, University Hospital, Uppsala,
Sweden. Experience of acute vascular access using Buselmeier shunt
and femoral catheters was evaluated in 76 intensive care acute renal
failure patients over 2 years (Jan 1987—Dec 1989). A total of 86 vascular
accesses were utilized of which 75% were Buselmeier shunts, 23%
femoral catheters and 2% Scribner shunts. No serious complications
were seen with the Buselmeier shunt which we have found safe to use
and it gives immediate access with adequate blood flow. It is also easy
to handle and bypass by a nurse in case of filter clotting. On the other
hand, 32 Hemasite devices were implanted in 28 chronic renal failure
patients with multiple vascular access problems over a period of five
years (April 1984—April 1989). Incidence of access failure was Ito 8 per
patient because they were high risk patients due to old age (60%) or to
presence of diabetes mellitus (29%). The outcome of the Hemasite
device as a solution for such access problems showed a one-year
cumulative survival of 55%. The high mortality rate (47%) in this group
(which was not related to the Hemasite) has affected this result.
However, 37% of the devices were lost due to thrombosis and infection
(31% and 6%, respectively). Two implants were removed because of
local and systemic infection. Stenosis was seen in 4 occasions of which
3 were corrected by PTFE grafts. The Hemasite is a useful alternative
for chronic vascular access problems as it gives an immediate and
painless access with adequate blood flow (900—1500 mI/mm) for hemo-
dialysis or hemofiltration treatments, but it should be reserved to
patients in whom a conventional angioaccess is truly difficult to obtain.
tn-line production of substitution fluid for hemodiafiltration using a
multipurpose system. J. Bergstrom, R. Nystrand, and J. Hardlund,
Department of Renal Medicine, Huddinge University Hospital, Stock-
holm, Sweden, Gambro AB, Sweden. Hemodialysis (HD) is no longer
the obvious treatment modality for the uremic patient. For patients at
risk of developing fl2m amyloidosis and patients with hemodynamic
instability either hemodiafiltration (HDF) or hemofiltration (HF) might
be the treatment of choice. To enable HD, HDF and HF a modified
AK-b HD-machine was developed (MPS-lO). The substitution fluid
was prepared on-line by means of pretreated RO water, a series of
ultrafilters and a microporous filter. The aim of this study was to
investigate safety and efficacy of this new multipurpose system. Two
patients treated with bicarbonate HD, chosen to benefit from HDF,
were included in the study. During 6 months, a total of 110 treatments
was performed. During the HDF treatment the patients' well being
improved as they reported less frequent intradialytic symptoms. The
patients temperature pre- and post-treatment was stabile with no febrile
reaction. The bacteriologic results showed a decrease from 22 positive
cultures out of 30 at the tap place to 1/29 before and 0/30 after the
prefilter and down the fluid line. There was a good correlation between
the bed-scale and machine information on fluid loss. The MPS-lO was a
pilot machine and further development is required to improve the
handling. We conclude that it is possible to produce bacteria free
substitution fluid on-line, and that Gambro's multipurpose machine was
safe and efficient.
Low.Ca (1.25 mmol/liter) dialysis and i.v. vltD in patients on chronic
hemodialysis. L. Brandi, H. Daugaard, P.K. Nielsen, L.T. Jensen, C.
Egsmose, and K. lgaard, Nephrological Department P, Rigshospita-
let, Copenhagen, Denmark. Forty-six patients on chronic hemodialysis
were treated for up to 6 months with reduced Ca4 (1.25 mmol/liter) in
the dialysis fluid. As a treatment and prophylaxis for secondary
hyperparathyroidism (HPT) patients were supplemented by 1 u(OH)D3
i.v. at the end of each dialysis in increasing doses, if p-Ca < 1.30
mmol. S-P was mainly controlled by CaCO3 and an increase in dose was
necessary. P-Ca, p-P. p-PTH, p-Alk.P, p-PicP and p-BGP were
measured every second week. Six patients were treated with CaCO3
alone (group I) and 40 patients were supplemented with la(OH)D3
(group 2). Nine patients were previously treated with I a(OH)D3 i.v. and
5 were given it orally. In group 1, PTH 1-84 was unchanged. In group 2
a reduction from 206 248 pg/mi to 131 203 pg/mI after 3 months (P
< 0.001) was observed. The PTH levels were still suppressed after 6
months to 169 222 pg/mI. Seven patients developed severe hyper-
phosphatemia (>2.5 mmol/liter). No suppression could be observed in
that group. In conclusion, reduced Ca (1.25 mmol/liter) in the dialysis
fluid is a safe procedure which allowed increasing doses of CaCO3 as a
P-binder and the use of I a(OH)D3 as an effective treatment and
prophylaxis of secondary HPT.
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Intermittent oral la(OH)D3 and low-Cat + (1.25 mmol/Iiter) dialysis in
patients on CAPD. L. Brandi, P.K. Nielsen, H. Daugaard, C. Egsmose,
L.T. Jensen and K. Olgaard. Nephrological Department P, Rigshospi-
talet, Copenhagen, Denmark. A direct suppressive effect of
1,25(OH)2D3 on the parathyroid gland has clearly been shown. The
peak concentration when 1 ,25(OH)2D3 is administered i.v. may be of
importance for this effect. However, due to the various ways of
administration it is of great interest to examine whether a similar
suppressive effect of vitamin D can be obtained by intermittent high-
dose oral administration. We have previously found a marked suppres-
sive effect on PTH secretion of la(OH)D3 i.v. 3 times a week to patients
on chronic hemodialysis. Usual Ca concentration in the CAPD
dialysis is 1.75 mmol/liter and oral 1 a(OH)D3 is often not possible due
to development of hypercalcemia. Therefore 13 patients on CAPD were
treated for 6 months with reduced Ca concentration in the dialysis
fluid. S-P was mainly controlled by CaCO3. If S.. < 1.30 mmol/liter
the patients were supplemented by intermittent oral 1 a(OH)D3 twice a
week in high doses. P-Ca, p-P, p-P'FH, p-Alk.P, p-osteocalcin and
p-PicP were measured every second week. A decrease in S** in the
dialysis fluid was observed (1.26 0.07—* 1.23 0.04, P <0.02) and
treatment with intermittent high dosage of oral 1 a(OH)D3 and an
increase in dose of CaCO3 were instituted. The further results will be
presented.
How well is the elderly hemodialysis patient doing? T. Buur, T.
Denneberg, M. Lundberg, and T. Timpka, Department of Nephrology,
University Hospital, Linkoping, Sweden. Under standardized condi-
tions, 62 chronic hemodialysis patients performed a self-assessment and
were evaluated independently by four nephrologists and four nurses.
The age of 33 patients was 65 years or more (old); 29 were younger
(young). There were no differences between young and old patients in
weekly treatment duration or the results of repeated urea kinetic
modelling, including "Kt/V" and protein catabolism. The old had a
median treatment time for ESRD of 22 months, the young 7 months.
There were no differences between young and old when doctors, nurses
or patients estimated the adequacy of dialysis, daily protein intake or
metabolic state. The evaluators were requested to state if the patient, in
their opinion, was doing better (+ 1) or worse (—1) than the "average
patients" (0). Average results of the evaluations are given below. For
comparison, evaluation of 12 diabetics (DM), 10 of whom were young,
is shown.
Old Young DM Non-DM
Doctors 02b 0.0 0.0
Nurses 00b 0.2 0.3c 0.2
Patients 0.3 0.3 o.oa 0.3
a P <0.05; b P <0.01; P < 0.001
The general tendency of the evaluations, doctors' < nurses' < pa-
tients', was statistically significant. There was a weak correlation (r =
0.23c) between frequency of dialysis side effects during the last two
months and the evaluations. However, the old had fewer side effects
(10.2% vs. 14.2%a). In conclusion, staff members state the old are doing
worse than the young, but this is not confirmed by the patients.
Diabetics are given lower ratings by both the staff and the patients
themselves.
Hepatitis C virus antibodies in dialysis patients in Denmark. F.
Knudsen, P. Wantzin, S.D. Ladefoged, N. LØkkegaard, K. Rasmus-
sen, L.S. Rasmussen, A. Lassen, and K. Krogsgaard, Departments of
Nephrology, Herlev Hospital, Hvidovre Hospital and Rigshospitalet,
and Department of Clinical Immunology, Hvidovre Hospital, Copen-
hagen, Denmark. Abnormal liver function tests are often observed in
dialysis patients. This has previously been attributed to non-A, non-B
hepatitis. The development of diagnostic tests for hepatitis C virus-
antibodies (anti-HCV) has shown HCV to be a major problem in
dialysis units. In a multicenter study we have investigated a population
of 340 chronic dialysis patients. The tests used were second generation
enzyme-linked immunosorbent assay (ELISA) from Ortho and recom-
binant immuno-blot assay (RIBA) from Chiron.
Center N
ELISA
Pos. (%)
RIBA
Pos. Ind.a Neg.
I
II
III
93
98
149
4(4%)
11(11%)
14 (9%)
2
6
8
2
2
5
0
3
1
Total 340 29 (9%) 16 9 4
a
The association between seropositivity and number of basic variables
(duration of dialysis, type of dialysis, number of blood transfusions and
biochemical liver function tests) was studied. In conclusion: The
presence of anti-HCV among chronic dialysis patients in Denmark
seems to be less compared to other dialysis centers in Europe but the
problem is not a negligible one.
Heparin therapy in chronic hemodialysis. Clinical experiences using a
new apparatus for heparin monitoring—the CoaTime Monitor. L.
Knudsen, J.P. SØrensen, J. lngerslev, and H.E. Hansen, Department
of Medicine and Nephrology C and Department of Clinical Immunol-
ogy, Skejby Hospital, University Hospital in Arhus; Novo Nordisk A/S
Copenhagen, Denmark. During hemodialysis (HD) surface interactions
take place at the interface between circulating blood and the dialysis
membrane leading to activation of platelets, leukocytes, complement
and coagulation factors, the latter necessitating anticoagulation to
prevent clotting. Heparin and heparinoids are widely used to prevent
clotting during HD. The aim of anticoagulation is to achieve the
maximal inhibition of the internal coagulation system with the least risk
of bleeding. Because patients respond very differently to heparin,
monitoring has been advocated. Several methods for monitoring of
heparinization during HD have been proposed. The aim of the present
study was to evaluate a new apparatus, The CoaTime Monitor" for
bedside monitoring of the whole-blood clotting. We investigated 118
courses of hemodialysis in 40 medically stable patients with chronic
renal failure (22 and 18 ). Double measurements were done on
capillary finger blood (C) as well as on aspirated blood from the arterial
site of the dialyzer (A). The CoaTime Monitora, times (CMT) were
compared to the activated partial thromboplastin time (APTT), mea-
sured by three different reagents, and functional heparin activity
(anti-FX, amidolytic method). During each course of HD measurements
were done before, during and at the end of dialysis. CMT showed a
good accuracy: r = 0.94, P < 0.0001 (C) - r = 0.99, P < 0.0001 (A),
inter-apparatus. A high correlation to anti-FXa was found: r = 0.86P <
0.0001 (C) - r = 0.78 P < 0.0001 (A). APTT was correlated to anti-FXa
(r = 0.74, r = 0.95, r = 0.87, P < 0.0001 for the three different reagents).
However, when samples were assayed using different APTT reagents,
inconsistent slopes were identified in the plots of APTT versus anti-
FXa, even if there was a clear correlation between the APTT time and
anti-FXa in each case. Conclusions: CMT correlates significantly to
anti-FXa and gives reproducible results comparable to APTF. In
addition, this bedside equipment is easy to use, time saving and cost
effective. The results from the APTT analysis are very dependent on the
reagent used because there is a great variation in sensitivity.
Effect of calcium carbonate administration to reduce serum phosphate
in dialysis patients. B. Stegmayr, M. Brännstrdm, Department of
Internal Medicine, University Hospital, Umeâ, Sweden. A high serum
phosphate in dialysis patients increases the risk for a secondary
hyperparathyroidism and other side effects. The supplementation of
phosphate binders containing aluminum has, for the most part, been
abandoned; mainly used instead are calcium salts of carbonate, glu-
conate or acetate. We investigated the effect of CaCO3 tables adminis-
tered to 8 patients on hemodialysis (HD-I) and 13 on peritoneal dialysis
(PD). The age range was 7 to 81 years and the proportion of women/men
was 7/14. The mean values were calculated of at least 3 consecutive
values of serum calcium and phosphate as well as intake of CaCO1,
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Mg(OH)2 and vitamin D. The tablets were ingested together with the
regular medicine between the meals. The same HD-patients then were
instructed to ingest the calcium carbonate, after chewing, during the
meal (HD-2). The amount of CaCO3 was increased without causing
hypercalcemia. Again analyses were performed of Sca and phosphate.
Comparison by Wilcoxon's or Student's tests were done. Results. The
mean values Of SCa were not significantly different in either study group.
The SPhosphat was not significantly different between the HD-1 or the
PD group (2.14 + 0.28 vs. 1.92 + 0.31). There was a significant decrease
in SPhophat in HD-2 compared to HD-l (P = 0.009). The CaCO3 dose
was not different between the PD group and the HD-l, but was
significantly greater in the HD-2 group (1 g/day to 1.6, P = 0.025). No
difference was present in Mg(OH)2 or vitamin D medications. Conclu-
sion. Administration of phosphate binders during the main meals was
shown to act favorably on serum phosphate levels. Patients should be
informed of this way of administration.
Clostridium difficile infection (CDJ)—A poor prognostic sign in uremic
patients. P. Stenvinkel, P. BarOny, C.E. Nord, and J. BergstrOm,
Departments of Renal Medicine and Oral Microbiology, Huddinge
University Hospital, Huddinge, Sweden. CDI has been reported in
uremic patients. Antimicrobial therapy is the major predisposing factor
to CDI in uremic patients, but other risk factors such as impaired host
defenses, arteriosclerosis with ischemic disease of the gut, old age,
malnutrition and poor general status are common in uremic patients.
This is a report of a CDI outbreak in a nephrology ward during a two
year period, 1984—86. One hundred and ten cases were encountered in
70 patients, of whom 62 had chronic renal failure (CRF) and 8 acute
renal failure. Ninety-six percent of the patients were uremic and treated
with either HD (50%), CAPD (30%) IPD (8%) or on a low protein diet
(8%). Most of the patients were female (58%) and elderly (64 2 years).
All patients were treated with vancomycin, often with dramatic im-
provement. Forty relapses of CDI were observed in 22 of the patients.
Six years later a follow-up study showed that 82% of the original 70
patients had died. Of these patients 49% had died during the first year
of follow-up. Seven patients were transplanted, 4 are on CAPD treat-
ment, I has only a moderate CRF and 1 is lost to follow-up. The serum
albumin concentration prior to the development of the CDI could be
obtained in 59 patients and was only 26 I g/liter, indicating malnu-
trition. Old debilitated uremic patients are especially susceptible to
CDI, which is a poor prognostic sign in CRF. Prompt treatment with
vancomycin should be started to avoid a severe course of the disease.
The use of integrated double-bag systems (IDBS) changes the incidence,
type, and associations of CAPD peritonitis (PE). E. Honkanen, A.-R.
Kala, and C. Gronhagen-Riska, University of Helsinki, Fourth Depart-
ment of Medicine, Division of Nephrology, Helsinki, Finland. Several
previous studies have shown that Y-shaped bag exchange systems are
able to reduce the incidence of CAPD PE. In this study, 67 patients (pts)
were allocated to use either traditional (single bag) systems (TRAD) or
IDBS (without disinfectant, Baxter DUO, Gambro GEMINI). The total
follow-up time was 317.5 months in the 33 patients on TRAD and 300.5
months in the 34 pts on IDBS. In addition, 13 patients first used TRAD
and were later switched to IDBS. The incidence of PE was 1.06/year on
TRAD and 0.7/year on IDBS. The probability of remaining PE free at 12
months was 29% and 59%, respectively (P = 0.03). In the 13 pts who
were switched from TRAD to IDBS, the PE incidence changed from
1.7/year to 0.7/year. The distribution of PE causing microbes on IDBS
was different from TRAD. While on TRAD the prevailing micro-
organisms (11/28) were coagulase negative Staphylococci, only I/li PE
episodes on IDBS was caused by these skin microbes. Staph. aureus
and Streptococci caused most of the PE episodes on 1DB 5, In 14/28 PE
episodes on TRAD there was some probable associated etiological
factor (exit site infection, disconnected transfer set, poor dental hy-
giene, etc.) while on IDBS there was some association in 10/11 episodes
(P < 0.05). Conclusions. (1) IDBS reduces the incidence of PE and
enhances the probability of remaining PE free, (2) coagulase negative
Staphylococci rarely cause PE on IDBS, (3) in PE on IDBS there is
more often some associated etiological factor. These results suggest
that (4) IDBS effectively reduces intraluminal contamination by skin
bacteria.
What contributes to poor appetite in CAPD patients? B. Hylander, B.
Barkeling, and S. ROssner, Department of Medicine, Division of
Nephrology, Karolinska Hospital, Stockholm, Sweden. Patients with
CAPD treatment often complain about poor appetite and rapid feeling
of fullness. The high concentrations of glucose in the dialysate or
abdominal discomfort because of the dialysate have been suggested as
plausible explanations. We reported in Dallas 1989 that no increased
intragastric pressure could be measured with full abdomen compared to
empty. We have now extended these studies to analyze the effects of
the dialysate on hunger and eating behaviour. A scale was built into a
table and connected to a computer which registered the intake of food
served upon a plate on top of the hidden scale. After a meal the
computer counted total amount eaten, eating velocity and eating time.
In connection with the meal the patient filled in formulas about hunger,
fullness and appetite. The patients came for lunch twice, once with full
abdomen, once without dialysate. Twelve men and four women partic-
ipated. Mean intake was 206 g full and 191 g empty and eating velocity
was 22 g/min and 25 g/min, respectively. These differences were not
statistically significant. On rating scales patients demonstrated prefer-
ences for protein before the meal which changed to carbohydrate
preferences after the meal as in healthy subjects. The study shows
quick feeling of fullness and low intake in CAPD patients and low eating
velocity compared to normals. No differences were shown between full
or empty abdomen, which indirectly implicates that higher sugar load
contributes to the feeling of fullness and is more important than the
discomfort caused by the dialysate.
Intra-abdominal location of peritoneal catheter tips in CAPD. P. Joffe,
A.-L. Christensen, and C. Jensen, Departments of Nephrology and
Radiology, Hvidovre Hospital, Copenhagen, Denmark. To examine the
movements of peritoneal catheter tips (PCT) during non-complicated
treatment of CAPD, we twice evaluated 1) in and outflow, 2) stability of
PCT location, and 3) patient's own impression of PCT location in
relation to fluoroscopy (F). Thirteen patients were included. No PCT
were located in the hypochondriac or epigastric regions. Outflow with
the PCT located in the middle part of the abdomen was significantly
lower (P < 0.02). No significant difference in inflow rate with respect to
PCT location in the middle part of the abdomen vs. the lower quadrants
were seen. Only one patient was able to state the exact location of the
PCT identical to F. F showed that 92% of PCT were located in the same
regions, whether patients were in upright or supine position. In conclu-
sion: 23% of patients had PCT displaced to the umbilical or lateral
regions of the abdomen showing a significantly lower outflow rate, PCT
nearly never moved when the patients changed position from upright to
supine positions, or vice versa.
Sclerosing peritonitis detected by type I and III procollagens. P. Joffe
and L.T. Jensen, Departments of Nephrology and Rheumatology,
Hvidovre Hospital, Copenhagen, Denmark. The carboxyterminal
propeptide of type I procollagen (PICP) and the aminoterminal propep-
tide of type LII procollagen (PIIINP) are split products related to the
formation of granulation tissue. Moreover, local concentrations reflect
the state of fibrogenesis. PICP and PLIINP were measured in serum (S)
and dialysate (D) in 14 CAPD patients. Mean levels for patients with
uncomplicated CAPD (N = 13) were:
tgIliter PICP PIIINP
Uncomplicated S 165 6(N=13) D 304 28
Sclerosing S 291 7
peritonitisa D 1400 209
One patient () had fivefold higher PICP and eightfold higher PIIINP in
the D. One month later, CAPD had to be stopped due to sclerosing
peritonitis. In conclusion: Our data suggest that determinations of PICP
and PIIINP in the dialysate could be a useful but non-specific marker of
sclerosing peritonitis.
Vitamin-D3 adsorption to peritoneal dialysis bags. P. Joffe, S.D.
Ladefoged, C. Cintin, H. Lehmann, and T. Storm, Departments of
Nephrology, Herlev Hospital and Hvidovre Hospital, Copenhagen,
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Denmark. This study was designed to determine adsorption of
I a(OH)D (I a) to CAPD equipment, and evaluate this adsorption in
relation to installation of albumin (± A), different glucose concentra-
tions (13.6/38.6 mg/mi), temperatures (23/37°C), and time. la (2 g/2
liter) was installed into the bag injection port. Aliquots were collected at
1, 5, 10, 20, and 60 minutes. The amount of Ia (g/iiter) left in the fluid
at different times were:
C° A
Glue
cone.
Minutes
1 5 10 20 60
23 — 13.6 0.42 0.44 0.42 0.47 0.46
37 — 13.6 0.67 0.58 0.64 0.60 0.62
37 — 38.6 0.36 0.38 0.42 0.31 0.42
37 + 13.6 1.04 0.94 0.91 0.94 0.80
These data demonstrate: 1) Ia adhered to dialysis bags instantly when
A was not installed (P < 0.01). 2) A temperature of 37°C impairs
adsorption of in at a glucose concentration of 13.6 (P < 0.05). 3) High
glucose concentration increased adsorption at 37°C (P < 0.01).
Low-dose subcutaneous rHuEPO in renal anemia in CAPD/CCPD
Patients. Interim analysis of a Swedish multicenter study. P. Barany,
Huddinge, N. Clyne, B. Hylander, Karolinska, A-C. Johansson, Sahi-
grenska, and 0. Simonsen, Lund; M. Magnusson, Linkoping, and C.
Frisenette-Fich, Jonköping, Sweden. The aim of this study was to
evaluate efficacy (target Hb >100 g/liter) and safety during up to 1 year
of treatment with s.c. rHuEPO. Inclusion criteria were all patients >18
years of age who had been on CAPD/CCPD for at least 3 months and
whose Hb was <90 g/liter. Up until the present date the study
comprises 31 patients (18 women, 13 men; mean age 57 years, range
20—79 years) with a mean time of 28 months (range 3—157 months) on
peritoneal dialysis. Eighteen patients required regular blood transfu-
sion. Pretreatment Hb averaged 76 g/liter (range 62—89 g/liter). After a
pretreatment period of 2 weeks, rHuEPO (RecormonK) was adminis-
tered at a dose of 20 LU/kg s.c. 3 times/week. If the Hb was still <100
g/liter after 10 weeks, or if a patient needed a blood transfusion after
treatment had commenced, the dose was increased by 60 lU/kg/week
and subsequently every 4 weeks if necessary. Results: At present the
treatment period ranges from 1—b months. Five patients were with-
drawn. Reasons for withdrawal were fatal AMI, kidney transplantation,
urinary bladder cancer, suspect minor stroke, nausea and unwillingness
to participate. Six of 29 patients had reached target hemoglobin after 10
weeks, 10 patients after three months and 16 of 22 patients after 6
months of rHuEPO treatment. Complications: (A.) Two patients devel-
oped increases in blood pressure treated by temporary withdrawal of
rHuEPO. (B.) Eight patients had 13 episodes of peritonitis; only 3 of 8
reached Hb >100 g/liter during the first 6 months of rHuEPO treatment.
(C.) No patient reported any local skin reaction from Recormon.
Conclusions: In 20% of the patients rHuEPO 60 IU/kg/wt s.c. sufficed
to reach Hb 100 g/liter within 2-1/2 months. Most of the other patients
seemed to need a higher dose. However, there was a low incidence of
hypertensive episodes which may be due to the relatively long correc-
tion period. Moreover, local tolerance to Recormon seemed to be
excellent. No serious side effects were reported.
Longitudinal study of life quality (QL) in hemodialysis (HD) patients
treated with erythropoietin (EPO). P. BOrány and E. Pettersson, De-
partment of Renal Medicine, Karolinska Institute, Huddinge University
Hospital, Stockholm, Sweden. Quality of life assessments were per-
formed in 24 HD patients (10 male, 14 female, age 44 3 years)
undergoing EPO treatment. Eight HD patients comprised the control
group. Survey questionnaires (112 items, divided in the dimensions of
physical, social and emotional well-being) were completed pre-treat-
ment (Hb 73 2 g/liter) and when the target Hb-value 100 g/liter was
reached (1—7 months). Eleven patients were investigated one year after
correction of the anemia. Pre-treatment the EPO group had significantly
more complaints about poor appetite, tiredness and irritability. No
significant changes were observed in five control patients, who were
investigated after 4—6 months. After correction of the anemia the EPO
group had significantly improved physical and emotional well-being.
The most significant changes were observed in health satisfaction,
physical activities of daily life and tiredness. Emotional symptoms like
depression and apathy were decreased. Only minor changes were
observed in the social well-being. After one year on maintenance EPO
treatment the physical and emotional well-being are still improved. In
conclusion, QL is improved during EPO treatment. The greatest
changes were seen in health satisfaction, physical activity and emo-
tional well-being. The improvements are maintained during long-term
treatment.
Effects of erythropoietin treatment on exercise capacity and renal
function in predialytic uremic patients. N. Clyne, T. Jogestrand, L-E.
Lins, and 5K. Pehrsson, Divisions of Nephrology and Cardiology,
Department of Medicine and Departments of Clinical Physiology,
Karolinska Hospital and Institute and Huddinge Hospital, Stockholm,
Sweden. Anemia is already present in patients with moderate renal
failure and is a major cause of the decline in exercise capacity seen in
these patients. We examined the effects of erythropoietin (EPO) treat-
ment in 12 predialytic uremic patients (EPO group: mean age 46 12
years; 6 men, 6 women) with a mean GFR of 10 4 mI/mm X 1.73 m2.
These patients were compared to a control group of 8 patients (5 men,
3 women). The observation period was 3 months. The EPO group
received 300 U/kg body wt i.v. once a week. The EPO group increased
their total hemoglobin (THb) from 323 89 g to 466 128 g (P < 0.001)
and their hemoglobin concentration (Hb) from 86 8 to 117 ii g/liter(P < 0.001). Their exercise capacity, measured by standardized exer-
cise test on a bicycle ergometer, increased from 128 45 to 147 57 W
(P < 0.05). The control group did not change their THb (349 124 and
357 131 g), Hb (93 8 and 94 10 glliter) or exercise capacity (98
49 and 101 50 W) during the observation period. There was a
significant correlation between the increase in THb and the increase in
exercise capacity in the EPO group (r = 0.81, P < 0.005). The GFR was
unchanged in both groups (EPO group: 10 4and 10 6 mI/mm x 1.73
m2; control group: 8 3and 8 3 mI/mm x 1.73 m2). The median renal
plasma flow did not change significantly in either group (EPO group: 42
and 27 mI/mm >< 1.73 m2; control group: 34 and 28 mI/mm X 1.73 m2).
The median filtration fraction, however, increased significantly in the
EPO group: 0.21 to 0.30% (P <0.05), while the filtration fraction in the
control group was unchanged: 0.22 and 0.25% (NS). We conclude that
erythropoietin treatment increases the THb in predialytic uremic pa-
tients, resulting in an improved exercise capacity without affecting
GFR.
EPO treatment of preuremic patients. B.G. Danielson, T. Salmonson,
B. WikstrOm, Renal Section, Department of Medicine and Medical
Products Agency, Uppsala, Sweden. So far the treatment of renal
anemia with recombinant human erythropoietin (rHuEPO) has mainly
been used in hemodialysis patients. However, anemia and fatigue are
often very common also in preuremic patients. A group of such patients
was therefore treated with rHuEPO. Twenty preuremic patients of
average age 45 years (12—86 years) were treated with EPO s.c. 1—3 times
per week. Follow-up time has been up to 3 years. The initial values
were as follows: hemoglobin 81 16 g/liter Scr 429 130 tmol/liter and
BP 156 26/83 11 mm Hg. Results. All patients responded to the
treatment, which was tolerated well. Average Hb value on treatment
was 114 12 g/l. 5Cr increased on treatment from 429 130 to 500
178 tmol/liter. Renal function deterioration evaluated from the three
years preceding the EPO treatment did not accelerate on treatment.
Side effects were very moderate. Conclusion. Treatment of renal
anemia in preuremic patients with rHuEPO is effective, has few side
effects and seems not to accelerate progress of the renal functional
deterioration.
Pharmacokinetics and pharmacodynamics of rHuEPO in CAPD pa-
tients. B.G. Danielson, T. Salmonson, andB. WikstrOm, Renal Section,
Department of Medicine and Medical Products Agency, Uppsala,
Sweden. Recombinant human erythropoietin is commonly used in
patients with chronic renal failure. CAPD patients often have relatively
high hemoglobin levels despite their uremia. The explanation for this
phenomenon is so far not known. Pharmacokinetics and pharmacody-
namics were investigated in 18 patients treated by CAPD. The pharma-
cokinetic parameters found in the CAPD patients were similar to
previous results in HD patients and healthy volunteers. Only small
amounts of EPO (<1%) were found in the dialysate after an i.v. dose.
The serum concentration-time curve after an i.p. dose was studied in 5
patients. The results were similar to a concentration-time curve during
a constant i.v. infusion. The amount of EPO absorbed from the
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abdomen was dependent on the dwell time of the EPO dialysate. After
24 and 48 hours, respectively, about 25 and 40% of the given dose was
absorbed. Fifteen patients on CAPD with a mean initial hemoglobin
value of 81 g/liter were treated with EPO s.c. until a hemoglobin of
100—120 g/liter was obtained. All patients responded to treatment. Few
side effects were observed. The average maintenance dose was much
lower than needed in HD patients with corresponding hemoglobin
levels. It could be concluded that the treatment was effective, well
tolerated and had few side effects. Intraperitoneal administration is
probably only cost effective in patients on IPD or CAPD where long
dwell times (>24 hrs) are possible or where i.v. or s.c. administration
has to be avoided.
The effect of erythropoietin on the progression of chronic renal failure.
I. Eidemak and M. Friedberg, Department of Nephrology, Herlev
Hospital, Copenhagen, Denmark. Correcting renal anemia with eryth-
ropoietin (rHuEPO) may accelerate the progression of chronic renal
failure. rHuEPO treatment in anemic rats with renal failure, induced by
five-sixths nephrectomy, led to greater systemic hypertension and
glomerular injury compared to nontreated controls. Studies on humans
have suggested that improving the hematocrit by means of transfusion
occasionally resulted in decreased renal function. To examine the effect
of rHuEPO on the rate of renal deterioration, GFR was estimated by the
plasma clearance of 51Cr-EDTA in eight predialytic patients 12 weeks
before, at baseline, and after 12 and 24 weeks of rHuEPO treatment.
The differences in GFR between baseline, 12 weeks before, 12 and 24
weeks after starting treatment were calculated in percentages. In
addition the slope of l/Sr versus time was determined before and
during treatment. Blood pressure was well controlled and rHuEPO
dosage was reduced when exceeding target hemoglobin (6.2—7.4 mmol/
liter). Based on our results we conclude that correcting anemia in
predialysis patients with rHuEPO does not accelerate the rate of decline
of renal function,
Lymphocytotoxic antibodies and immune reactivity in vitro in EPO
(erythropoietin) treated hemodialysis patients. I. Fehrman, P. BOrány,
and A. Lindholm, Department ofRenal Medicine, Clinical Immunology
and Transplantation Surgery, Huddinge Hospital, Huddinge, Sweden.
Twenty-six patients in regular hemodialysis were given EPO to correct
renal anemia. At the start of treatment 10 patients had lymphocytotoxic
antibodies detected by positive reactions against a panel of T lympho-
cytes (PRA-positive). A significant reduction of PRA from 60% to 35%
(P < 0.05) occurred during the following 12—18 months. Three of 26 had
to be given blood transfusions due to intercurrent disease. In these
patients PRA increased. Kidney transplantation was performed in 14 of
the 26 patients. Five of these patients were PRA-positive at the start of
EPO and 4 have currently functioning grafts. Immune reactivity in vitro
measured as response in MLC and after T-cell stimulation showed
significantly lower responses with lymphocytes from the uremics com-
pared to controls (P < 0.001). Despite correction of anemia the low
responses did not change. Conclusion: EPO treatment seems of great
advantage in immunized patients, since the antibodies disappear with
time. The low immune reactivity does not change, favoring the outcome
in kidney transplantation.
Plasma erythropoietin (EPO) concentration after a single i.p. dose of
recombinant human EPO during continuous ambulatory peritoneal dial-
ysis. T. Forslund, A. Relander, and F. Fyhrquist, Central Hospital,
Jyvaskylä, and Minerva Institute for Medical Research, Helsinki,
Finland. Recombinant human erythropoietin (rHuEPO) is effective in
the treatment of anemia in patients undergoing hemodialysis or contin-
uous ambulatory peritoneal dialysis (CAPD). Mostly, rHuEPO is given
intravenously (i.v.) or subcutaneously (s.c.). It may also be given
intraperitoneally (i.p.) into the CAPD bags, but then much higher doses
may be needed to achieve acceptable values of hematocrit. We gave
rHuEPO in a single i.p. dose to 4 patients, mean age 40 years, who were
undergoing dialysis by CAPD. EPO was given in a concentrated form
1/2 hour prior to installation of the morning dialysate bag. 8000 IU of
rHuEPO diluted into 100 ml of 0.9% NaCl was infused into the emptied
peritoneum. Plasma EPO concentration was measured by a radioimmu-
noassay after 1/2, 1, 2, 4, 6, and 24 hours, respectively. The baseline
plasma EPO concentration (mean so) was 6.4 pmol/liter. After
installation of rHuEPO into the dialysis bag, the plasma EPO concen-
tration (pmol/liter) increased to 8.9 (± 5.1; P < 0.05), 9.8 (± 5.1, P <
0.01), 10.9 (± 8.8, NS), 15.4 (± 8.1, P < 0.01), 17.3 (± 8.8, P < 0.02),
and 15.8 (± 6.0; P < 0.01) after 1/2, 1, 2, 4, 6, and 24 hours,
respectively. The plasma EPO level increased by 170% and 147% after
6 and 24 hours, respectively. The absorption of rHuEPO continued
after termination of the EPO infusion, and changing of dialysate fluid
did not reduce EPO absorption. rHuEPO might be given i.p. when a
high concentration form is used and the peritoneum is emptied.
Central hemodynamics following treatment with erythropoietin. H.
Frandsen, I. Eidemak, S. Ladefoged, M. Friedberg, M. Skielbo, N.F.
Andersen, and S.L. Nielsen, Departments of Clinical Physiology,
Clinical Chemistry and Nephrology, Herlev University Hospital, Den-
mark. Eighteen hemodialysis patients were studied before and 3 months
after treatment with rHuEPO. Cardiac function was determined by a
cardiac isotopic method. The venous hematocnt increased from 27 2
to 36 1% (mean SEM). Plasma volume decreased from 3.8 0.2 to
3.1 0.2 liter. The total blood volume calculated from the latter values
or determined by a direct (carbon monooxide) method was unchanged.
In 7 patients there were no changes in cardiac function: cardiac output
(CO) (4.9 0.6 vs. 5.1 0.6 liter/mm), ejection fraction (EF) (58 3
vs. 60 5%) and stroke volume (SV) (61 8 vs. 61 8 ml). Four
patients with an unaltered EF (53 4 vs. 53 6%) had a decrease in CO
(7.0 1.0 vs. 4.1 0.7 ml) and SV(79 10 vs. 56 11 ml) mainly due
to a reduced end diastolic volume (147 8 vs. 109 20 ml).
Conclusion: During EPO treatment a significant decrease in plasma
volume is not accompanied by changes in total blood volume. Cardiac
function is unaltered in most patients.
Hemodynamic effects of treatment with recombinant human erythro-
poietin in patients on maintenance hemodialysis. A preliminary report. C.
Ha?dersdal, J. Mehlsen, D. Stenver, L. Jeppesen, B. Nielsen, and K.
Winther, Department of Clinical Physiology, Nephrology and Clinical
Chemistry, University of Copenhagen, Hvidovre Hospital, Denmark.
The long-term hemodynamic effects of recombinant human erythropoi-
etin treatment were investigated in eight hemodialysis patients by
means of indicator dilution method, auscultatory blood pressure mea-
surement and palpatory pulse registration. The table shows the results
in mean values before and after four and six months' treatment.
Measurement Before
4
months
6
months
Hematocrit % 26 36 36
Cardiac Index I x min' X 3.73 3.73 3.80
m2
Mean arterial pressure mm Hg 105 107 109
Peripheral resistance 1463 1517 1525
dyn x sec x cm5
Heart rate min' 83 82 81
Plasma volume ml x kg_I 58.8 54.2 51.7
Blood volume ml x kg 75.7 77.1 77.8
Erythrocyt volume ml x kg_I 16.9 22.9 26.1
The hematocrit and the erythroeyt volume were significantly increased
and the plasma volume decreased (P < 0.05). It is concluded that
erythropoietmn treatment results in increased capacity for oxygen trans-
portation in patients on maintenance hemodialysis without compromis-
ing their cardiovascular status.
Subcutaneous (s.c.) versus i.v. administration of rHuEPO. S.D. Lade-
foged, M. Friedberg, I. Eidemak, M. Skielboe, E. Pedersen, and H.
LØkkegaard, Department of Nephrology, Herlev, Denmark. The most
effective route of administration of rHuEPO remains uncertain. Pro-
spectively we studied s.c. versus i.v. administration in three compara-
ble groups of patients: Hemodialysis (HD) iv. (N = 11), HD s.c. (N =
9)and continuous ambulatory peritoneal dialysis (CAPD) s.c. (N = 10).
All three groups received initially 50 U/kg three times a week. The first
8 weeks adjustments were done only if Hb level exceeded target Hb (>7
nmol/liter). We evaluated time to reach target Hb (TTHb days),
cumulative doses to target Hb (CTHB U/kg) and maintenance doses
(MA U/kg/wt). (Median and 25—75% percentile)
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TFHb CTHb MA
HD i.v. 84 2066 125
(N = 11) (42—98) (1673—2066) (86—165)
HD s.c. 42 924 63
(N = 9) (14—77) (693—1473) (20—85)
CAPD s.c. 42 872 72
(N = 10) (28—56) (571—1135) (31—100)
Total observation period after target HB was 130 (114—264) days.
Conclusion: s.c. administration is significantly more effective than i.v.
administration in induction and maintenance therapy in both HD and
CAPD patients.
Impaired erythrocyte fluidity during treatment of renal anemia with
erythropoietin. T. Linde, B. Sandhagen, B.G. Danielson, and B.
Wikstrdm, Departments of Internal Medicine and Clinical Physiology,
University Hospital, Uppsala, Sweden. The erythrocyte ability to
deform, or the erythrocyte fluidity (E-flu), is known to be impaired in
uremia. Besides the whole blood viscosity (B-visc), plasma viscosity
(P-visc) and erythrocyte aggregation tendency (E-aggr), the E-flu is
assumed to be of importance for the flow resistance especially in very
small blood vessels. Seventeen hemodialysis patients with renal anemia
were treated with recombinant human erythropoietin (rHuEPO). The
hemorheological variables mentioned above were analyzed every sec-
ond week. The E-flu was measured as the inverse of the low shear rate
viscosity (0.95 s ') of washed erythrocytes resuspended to a hematocrit
of 55%. In that way all effects of plasma and Hct on the low shear rate
viscosity were eliminated. Before start of treatment the E-flu was
decreased, however, not significantly, compared to a reference group of
healthy individuals. During treatment the E-flu decreased further and
reached its minimal level after 18 weeks. As soon as the hemoglobin
concentration had reached its steady state the F-flu started to increase,
and later it reached values equal to those seen before start of treatment.
There was a significant increase in B-visc. The B-visc and Hct devel-
oped in a parallel fashion. No changes were seen in P-visc and E-aggr.
The cause of the impaired E-flu seen during treatment with rHuEPO is
unknown, but might be of importance for the development of hyper-
tension often seen during rHuEPO treatment.
Treatment of (pre-)dialysis patients with rHuEPO doesn't affect the
peripheral blood lymphocyte profile. G. Steffensen, J. V. Povisen, and
N.A. Aunsholt, Department of Medicine C, Aalborg Hospital, and
Department of Clinical Immunology, University Hospital of Aarhus,
Skejby Sygehus, Denmark. We have previously shown that lymphocy-
totoxic antibody titer and broad reactivity in sensitized renal patients
may decline during rHuEPO treatment. The aim of the present study
was to investigate whether rHuEPO treatment affected the peripheral
blood mononuclear cell (PBM) profile. Fifteen patients with progressive
(predialysis) or end-stage (CAPD or HD) renal failure were included.
They were bled before and 1, 2, 3, and 6 months after starting rHuEPO
administration. Using two-color flow cytometry, the absolute and
relative number of PBM in the following subsets were determined:
T-cells (CD3) and T-cell subgroups (CD4, 8, 29, and 45R); mature
B-cells (CD2O); mature monocytes and macrophages (CD 14); natural
killer cells, N K-cells (CD 16) and bone marrow progenitor cells (CD34).
All patients responded with sufficient correction of the anemia.
Throughout the study, we observed a remarkable intraindividual Con-
stancy in the relative distribution of the PBM subsets, but a pronounced
interindividual variability. Some fluctuations were recorded in the
absolute lymphocyte count, but these were without any obvious pat-
tern. No bone marrow progenitor cells could be found in the peripheral
blood. Our results demonstrate that rHuEPO treatment does not affect
the relative distribution of PBM. The effect seems mainly restricted to
the erythropoiesis.
Subcutaneous administration of erythropoietin to dialysis patients. B.
Stegmayr and H. Sandgren, Department of Internal Medicine, Univer-
sity Hospital, Ume, Sweden. The administration of intravenous eryth-
ropoietin (EPO) is easy to perform in patients on hemodialysis (HD)
while patients on peritoneal dialysis (PD) often choose this dialysis
technique in order to avoid frequent contact with the hospital (i.e. long
distance). To facilitate the administration of EPO we, during the last 2
years, mainly have used s.c. administration once weekly with results
given below. Material: 30 dialysis patients (18 men 12 women) with a
median age of 63 years (28—80 years) were given EPO due to anemia in
the course of chronic renal failure (HD = 11, PD = 19). EPO (Eprex,
Cilag AB, Sollentuna, Sweden) was administered s.c. once weekly in 28
patients and twice weekly in 5. The mean value of blood-hemoglobin
(B-Hb) prior to start of EPO administration was 81 g/liter (range 66—97,
PD group = 80.6, HD = 81.6). Eleven patients had a hemoglobin of less
than 80 g/liter. Iron was supplemented if necessary. Results: Twenty-
four patients achieved B-Hb of 90 or higher (PD = 89%, HD = 67%)and
16 a B-Hb of 100 g/liter or higher (PD = 63%, HD = 33%). The mean
dose (units) given weekly to achieve a mean B-Hb value of 80—113
glliter in a group of 16 patients is given below. Five of them had B-Hb
less than 80 at start.
I—I—I-I.
80 90 100 110 120
Blood hemoglobin, glliter
Side effects caused withdrawal of EPO in two of 30 patients (headache,
hypertension, conjunctivitis). If more than 6000 units were necessary
the dose was often divided into two subcutaneous administrations per
week. Conclusion: Subcutaneous administration of EPO once weekly
is, in most patients, a convenient way to sufficiently obtain adequate
increase in blood hemoglobin.
Recombinant human erythropoietin improves erythrocyte osmotic re-
sistance and has no effect on platelet aggregation activity. A preliminary
report. D. Stenver, L. Jeppesen, K. Winther, C. Ha!dersdal, J.
Mehlsen, and B. Nielsen, Departments of Nephrology, Clinical Chem-
istry, Clinical Physiology, Copenhagen University Hospital, Hvidovre,
Denmark. In the present study we investigated changes in erythrocyte
osmotic resistance, platelet number, size and aggregation activity,
during treatment with recombinant human erythropoietin (EPO). Eight
clinically stable patients with end-stage renal disease, maintained by
hemodialysis, received thrice-weekly an i.v. bolus of EPO. Initially the
dose range was 50—80 I. U ./kg (M 70), with subsequent adjustments
dependent on the response. Blood was collected before start of EPO
therapy, and after 3 and 5 months. The average baseline hematocnt value
was 25%, and at the time of the second and third examinations 33% and
32%, respectively. The measure for erythrocyte osmotic resistance
changed significantly (P < 0.01), from 135.0 ARB/units to 128.6
ARB/units at the time of the third test. No change in platelet number or
size was observed. Platelet aggregation induced by ADP, adrenalin,
collagen and thrombin did not show any significant alterations. Our
results suggest that the erythrocytes have a reduced hemolytic ten-
dency during EPO treatment. Platelet activity is not increased.
Effects of recombinant human erythropoietin (rHuEPO) for correction
of anemia in patients on long-term hemodialysis (HD). L. Weiss, T.
Wentzel, C. Frisenette-Fich, E. Hoffstedt, K. Lindberger, G. Mascher,
F. Nielsen, K. Prütz, and P. Wessén, Medical Clinics in Karlstad,
JOnkoping, Visby, Ostersund, Bollnäs, Boris, Helsingborg and Gävle,
Sweden. This study attempted to answer if an EPO dose of 40 IU three
times weekly gives adequate response regarding the hemoglobin level.
Seventy patients aged 19—85 (mean 60) were included in the study. They
had all been on HD treatment for at least 6 months and had Hb levels
of 90 g/liter or an anemia with a need for more than 3 transfusions
during the last 6 months. After a pretreatment period we started EPO
treatment with 40 lU/kg x 3/week i.v. after HD. If the Hb rise was less
than lOg/liter after 6 weeks or if the target Hb level (100 g/liter) was not
reached after 6 weeks the EPO dose was increased with 40 IU X 3/week
every fourth week. Iron supplementation was given with 200—300
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mg/day to patients with low or normal levels. Results. After 6
months the mean hemoglobin level had increased from 75.3 7.8 to 103
14.8 liter and 40 patients (76%) were on treatment with a dose of 40
lu/kg x 3/week. The patients that after 6 months were on treatment
with 40 lU/kg x 3 week started with a mean SFer,.tIn level of 263 519
sg/liter, and had after 6 months a higher mean Se,.,.itin level 231 305
sg/liter than those on treatment with 80 lU/kg x 3/week whose mean
level at start was 136 188 and after 6 months 71 42 sg/liter.
The patients needing high EPO doses were not characterized by high
SAl or high intact PTH levels. Conclusion. EPO treatment with a
starting dose of 40 lU/kg x 3/week gives adequate Hb levels in more
than 50% of patients. Patients needing higher doses of EPO seemed to
have lower iron stores (measured with Sperntjn), thus suggesting that a
more active iron supplementation treatment should be used.
Prevalence of cardiovascular risk factors after renal grafting. S.
Aakhus, K. DahI, T.E. Widerøe, and S. JØrstad, Department of
Medicine and Nephrology, Regional Hospital of Trondheim, Trond-
heim, Norway. To assess the prevalence of cardiovascular risk factors
after renal grafting a cross sectional, Norwegian multicenter study was
done. Data from 166 renal grafted patients have so far been analyzed.
Mean age s of the patients was 45 16 years. Immunosuppressive
treatment was CsA + Aza + prednisone in 47%, Aza + prednisone in
30% and CsA + prednisone in 20% of the cases. Hypertension was
present in 35% and diabetes mellitus in 18% of the cases. ECG
demonstrated left ventricular hypertrophy in only 4%, and ischemia
and/or old infarction in 9% of the cases. Thirty percent of the cases
were smokers. Mean values SD for total cholesterol was 7.3 1.7
mmol/liter; HDL cholesterol 1.40 0.44 mmol/liter; triglycerides 2.6
1.7 mmol/liter. The mean ratio SD of LDL cholesterol to HDL
cholesterol was 3.8 1.9 mmol/liter. We preliminarily conclude that
renal grafted patients in general have an increased risk of cardiovascu-
lar morbidity. This is so in all age groups. Furthermore, male sex, S1,.
> 125 mo1/liter and the use of diuretics and beta blocker therapy was
associated with an unfavorable lipid profile and an increased risk of
cardiovascular morbidity. Results from approximaterly 420 renal
grafted patients will be presented at the meeting.
Bone metabolism in renal transplanted diabetic patients with periph-
eral fractures. U. Backman, H. LindstrOm, K. Larsson, E. Lindh, S.
Ljunghall, and K. Obrant, University Hospital, Uppsala and Orthope-
dic Clinic, Allmãnna sjukhuset MalmO, Sweden. During the last years
we have observed an increased number of fractures caused by small
trauma among diabetic patients who have received a renal transplant.
This has occurred in spite of a low dose regimen of steroids to
transplanted patients. In addition, treatment with steroids usually
causes so-called axial osteoporosis. In a pilot study we have investi-
gated three transplanted diabetic patients with fractures of the foot. The
patients were men aged 30-43 years with a duration of the diabetes of 20
years. Two patients had been dialyzed for one and two years, respec-
tively. The third patient got living donor transplantation before he
needed hemodialysis. All three patients had foot fractures after trans-
plantation from a very small trauma. The patients were investigated
regarding bone density with SPA (single photo absiometry) in the distal
forearm. Bone biopsies were taken from the hip crest after treatment
with tetracyclin. The biopsies were investigated with histomorphome-
try. The blood was investigated for alkaline phosphatase, albumin,
calcium, creatinine, vitamin D and PTH (the intact molecule). Results.
All patients had normal values of calcium, but one patient had an
elevated PTH. This patient also had a serum creatinine of 291 smol/
liter, while the others had a creatinine of 133 and 129 mol/liter. All
patients had normal alkaline phosphatase but 25-OH-vitamin D3 was
slightly increased in two patients. 1,25-hydroxyvitamin D3 was, how-
ever, normal in all patients. Two patients had severely decreased SPA
and one patient had a slightly decreased value. Histomorphometry of
the bone biopsies showed evidence of osteomalacia in all three patients.
Conclusion. From the clinical point of view and from the results from
the SPA all patients had a peripheral osteoporosis. In addition, all
biopsies showed that all three patients had osteomalacia, which was a
surprise. The last finding gives some hope that some of the skeletal
problems in these patients might be preventable. We plan to expand the
study, and as a control group also investigate diabetic patients before
the transplantation.
Effects of isradipine on pharmacokinetics and renal function in cyclos-
porin A treated renal transplanted patients. K.J. Berg, L. Endresen, H.
Holdaas, P. Fauchald, D. Solbu, Sections for Nephrology and Clinical
Chemistry, National Hospital, Oslo, Norway. Isradipine (IS) is a
dihydropyridine calcium channel blocker. The pharmacokinetic inter-
actions between IS and cyclosporin A (CsA) and the effects of IS on
renal function were studied in 12 CsA-treated renal graft recipients with
stable renal function (Sr 1.57 0.12 mg%). The patients were given IS
1.25 mg x 2 for I week and 2.5 mg > 2 for the next 2 weeks in a placebo
controlled study. The CsA dose was unchanged in all patients [mean
trough blood CsA (monoclonal RIA) 75—175 ng/ml]. IS did not influence
the pharmacokinetics of CsA as both blood levels of CsA (specific RIA)
and CsA + metabolites (unspecific RIA) were unchanged compared to
the placebo period. IS reduced MAP from 117.0 1.8 to 106.3 1.9
mm Hg (P < 0.01). The effects of IS on renal function (mean SEM) are
summarized.
Placebo Isradipine
C1, mI/mm 59.6 6.0 59.3 6.7
CPAH mI/mm 256.4 21.5 291.5 26.3a
CLI mI/mm
PFR (1 — CL/C!,.)
RVR units
24.4 3.2
0.59 0.03
0.28 0.02
28.5 34
0.52 004b
0.22 0O2
a p < 0.05
b p < 0.01
The urinary excretion of enzymes (NAG, ALP, kallikrein) and proteins
were unchanged by IS. In conclusion, IS increased RBF and reduced
RVR and PFR, and thereby counteracted the CSA-induced hemody-
namic effects on the kidney.
Toxicity of cyclosporin A and cremophor to a kidney epithelial cell line,
LLC-PK1 cells. A. Bergstrand, L. Nässberger, and J. W. DePierre,
Research Center, Huddinge Hospital, Huddinge; Department of Med-
ical Microbiology, University of Lund; Unit for Biochemical Toxicol-
ogy, University of Stockholm, Stockholm. The present study describes
the morphology of LLC-PK1 cells and compares this to the appearance
of proximal tubule cells. In addition, it has been demonstrated that at
high concentrations cyclosporin A and, to a lesser degree, its vehicle
cremophor are toxic to LLC-PK1 cells, and at intermediate concentra-
tions also alter intracellular morphology in this same system. It was
found that the difference between toxic (0.3 m and non-toxic (0.2 mM)
concentrations of cyclosporin A during a 24-hour exposure was rela-
tively small, suggesting that a sharp threshold for cytotoxicity might
exist. Cells incubated with CsA 75 /tM survived for 4 days, correspond-
ing concentration for cremophor was 0.1%. Furthermore, we have
found that Nile red can be used as a fluorescence probe for the rapid and
simple detection of drug-induced lipid-rich structures in cell cultures.
Serum erythropoietin levels in the immediate kidney post-transplant
period. J. Goch, G. Birgegird, B. Wikström, G. Tufveson, and B.G.
Danielson, Departments of internal Medicine and Surgery, Transplan-
tation Unit, University Hospital, Uppsala, Sweden. Following success-
ful kidney transplantation, renal anemia is gradually corrected during
the first three to four months. The aim of the present study was to
investigate how transplantation procedures influence the serum EPO
levels early after kidney transplantation, with special emphasis on the
initial 24 hours following transplantation with grafts from living (N = 8)
and cadaveric (N = 8) donors. Sixteen patients, 13 men and 3 women,
were studied before and up to 15 days after kidney transplantation. All
but four patients received dialysis treatment before transplantation
(hemodialysis N = 11, CAPD N = 1, predialysis N 4). Results.
Significant increase in serum EPO was seen 8 hours after transplanta-
tion, and a first peak was noticed after 24 hours. Despite a considerable
difference in cold ischemic time there was no significant difference
between the two groups. After 9—il days serum EPO reached levels
which usually are observed during the first months following transplan-
tation. Conclusions. An increase in serum EPO levels occurs early
post-transplant. In spite of severe anemia, moderate serum EPO levels
are reached which, however, seem enough to correct anemia.
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Causes for hypertension after renal transplantation (Tx). C. GrOn-
hagen-Riska, T. Tdrnroth, P. Nyldnden, E. Honkanen, IVth Depart-
ment of Medicine, University of Helsinki, Finland. Risk factors for
hypertension (HT) after cadaveric renal Tx were analyzed in 66
patients. Forty-eight received antihypertensive therapy; 18 were nor-
motensive (NT). Mean age was 47 years in both groups, and mean
period post-Tx (36/35 months) was similar. All but 7 patients had
received low-dose cyclosporine (CsA), but NT had received a higher
mean cumulative CsA dose: 247.5 versus 167.5 g (P = 0.033). Before
Tx, blood pressure had been somewhat lower in the NT group: 146/84
versus 156/86 (P = 0.078/0.557), but only 7/18 versus 39/48 had been on
anti-hypertensive therapy (P < 0.001, chi-square). Most diagnoses were
equally distributed, but only 1/18 NT versus 13/48 HT had diabetic
nephropathy (P = 0.06). HT and NT did not differ with regard to Sr
level, nor were there any differences between donor age, cold ischemia
time, the number of HLA-AB or -DR mismatches, or the number of
acute rejections. Tx biopsy was performed in all patients; results are
available from 27 (10 NT/17 HT). When blindly scored from 0—3, mean
values of tubular atrophy, interstitial fibrosis (IF), and intimal hyper-
plasia were similar in groups. Arteriolosclerosis was slightly more
common in the NT (1.1 vs. 0.6, P = 0.194), IF correlated with the
corresponding Sc,. value (r = 0.5, P = 0.037). In conclusion, pre-Tx HT
and diabetes proved risk factors for HT after Tx. Contrary to general
belief restricted CsA use did not protect from this complication; HT
patients had received less CsA, which may indicate insufficient long-
term immunosuppression and chronic rejection + HT. Possibly CsA-
induced histopathological changes were equally common among NT
and HT patients.
Diltiazem and cyclosporin A kinetics in renal transplant patients. M.
Hammer, E. Pedersen, S. Ladefoged, and K. Rasmussen, Department
of Nephrology, Herlev Hospital, Copenhagen, Denmark. This study
was performed on 20 patients, participating in a randomized, placebo
controlled, double-blind study of the effect of diltiazem (DIL) on renal
graft function. Studies were performed at the earliest 10 days after tpx.
when graft function was stable. Peroral and i,v. CsA kinetics were
measured while they were on peroral treatment with DIL or placebo
(PLA), and peroral kinetics of CsA was further measured once after
they had abstained from the DIL/PLA test tablets for 24 hours. Whole
blood CsA was measured with a specific RIA as well as with a
polyclonal antibody. Whereas CsA trough levels did not differ, the po
dose was 102 9 and 134 13 mg/day (P < 0.05). The kinetics: Time
to maximum (Tmax), clearance (CL), area under curve (AUC), and
half-life (HL) were measured. In contrast to peroral kinetics, iv.
kinetics parameters did not differ. Table below shows means SE of
peroral kinetics as measured with the monoclonal specific RIA.
AUC Tmax HL CL
DIL(+) 2192 294 149 30 300 47 13 2
DIL(—) 1667 398 253 38 332 71 36 7
PLA(+) 1801 200 175 44 459 90 23 5
PLA(—) 2183 451 251 38 296 53 28 12
a Differences were more pronounced for metabolite sensitive assay.
The data suggest that DIL primarily affects CsA kinetics on the
absorption level and first pass metabolism in the liver.
Changes in renal biopsies during low dosage cyclosporine admirnstra-
tion. H.E. Hansen, H. Zachariae, K. Kragballe, and T. Steen Olsen,
Departments of Medicine and Nephro!ogy, C. Skejby Hospital; Depart-
ment of Dermatology, Marselisborg Hospital; Department of Pathol-
ogy, Aarhus Kommunehospital; University Hospitals in Aarhus, Swe-
den. Studies on pre- and post-treatment renal biopsies in eleven
psoriatics and five patients with systemic sclerosis treated with 1.5—7
mg/kg cyclosporin A per day for approximately one year showed
changes which were conceivably related to therapy. The findings
developing between the two biopsies were slight interstitial fibrosis,
slight to moderate tubular atrophy, and slight to moderate hyalinosis
and sclerosis of arterioles. All biopsies were investigated with a blind
morphometric evaluation using a point count method. The changes in
interstitial fibrosis were significant for the group as a whole, as well as
for the psoriatics alone (P < 0.04). Our studies give no information
about the clinical relevance of the minor changes found hitherto and by
no means exclude the use of cyclosporin A in these diseases. They,
however, indicate the importance of further studies of renal changes
during long-term low-dosage cyclosporin A therapy.
Renal function of the living kidney donor and his recipient. A.L.
Kamper, S. Strandgaard, P.P. Leyssac, N.H. Holstein-Rathlou, P.
Skaarup, and 0. Munck, Departments of Nephrology, Urology, Clini-
cal Physiology, Herlev Hospital; Institute of Experimental Medicine,
University of Copenhagen, Denmark. Glomerular and tubular function
was studied in 18 living kidney donors and their recipients in order to
compare the changes after uninephrectomy (Nx) and transplantation(Tx). Clearances of 51Cr-EDTA (GFR), lithium (CLI) sodium and
potassium were measured before Nx and 5, 12, 26, 54 days after Nx/Tx.
The fraction of clearance values ascribed to the remaining and trans-
planted kidneys was determined from the distribution of donor renog-
raphy. In donors, GFR rose from mean (sD) 49 (8) to 62 (10) mI/mm at
5 days after Nx (P < 0.01) and remained at this level. CL rose from 13
(3) to 21(7) mI/mm at 5 days after Nx (P < 0.01) and remained elevated.
In recipients GFR rose gradually from 47 (8) to a significantly elevated
level of 60 (13) mI/mm only at 54 days after Tx (P < 0.05). CLI had not
risen at 5 days after Tx but rose to 18 (8) mI/mm at 12 days after Tx (P
<0.05), and then further increased to 22 (6) mI/mm at 54 days after Tx
(P < 0.01). To conclude, hyperfiltration and depression of fractional
proximal sodium and water reabsorption was delayed in the trans-
planted kidney as compared with the remaining kidney of the donor.
Diltiazem (D) and renal transplantation (RT): A prospective, random..
ized, placebo (P) controlled, double-blind study. S.D. Ladefoged, M.
Hammer, E. Pedersen, C.B. Andersen, K.C. Rasmussen, F.M.
Hansen, K. Rasmussen, Departments of Nephrology and Pathology,
Herlev Hospital, Herlev, Denmark. Calcium channel antagonists have
been reported to improve the results of renal transplantation. We have
studied the influence of D/P on delayed graft function (DGF), rejection
(REJ), rerejection (RREJ), creatinine clearance (Ccr ml/min), and graft
survival (OS) in the first 3 months after RT. All kidneys were reperfused
with D/P immediately before transplantation. All recipients received a
bolus injection of D/P (0.3 mg/kg) before RT followed by a constant
infusion (3 mg/kg/day) and later D/P 60—120 mg t.d. perorally. All
received conventional triple immunosuppression aiming at a cyclospo-
rine whole-blood trough level of 250—400 ng/ml. REJ were treated with
prednisolone and RREJ with OKT3. Graftectomy had to be performed
in 3D/IF within the first week due to thrombosis. Data presents the
remaining patients.
No.
DGF REJ RREJ Ccr
m+SEM
GS
%%
DIL 16 69 38 0 39 + 8 88
PLAC 19 58 42 16 41 + 7 74
Conclusion: Diltiazem does not reduce the incidence of delayed graft
function or rejection and does not improve graft function, but may
reduce rerejection and improve graft survival.
Metabolism of prednisone in kidney transplanted patients with necrosis
of femoral head. G.S. Lausten, M, Egfjord, and K. Ølgaard, Depart-
ments of Orthopedic Surgery U and of Medicine P, Division of
Nephrology, Rigshospita!et, University of Copenhagen, Denmark. To
evaluate the role of the metabolism of prednisone for the development
of osteonecrosis after renal transplantation, the metabolism of pred-
nisone 20 mg p.o. and of prednisolone 20 mg iv. on two different
occasions was compared in 6 kidney transplanted patients with necrosis
ofthe femoral head to 6 and sex-matched kidney transplanted patients
without this complication. Total plasma prednisolone, prednisone and
cortisol concentrations were determined by HPLC. No difference was
found in body weight, renal and liver function tests, serum protein or
baseline plasma cortisol levels between the groups. Peak prednisolone
levels after p.o. administration, bioavailability and the volume of
distribution of prednisolone were also similar in the two groups.
However, the metabolic clearance of prednisolone in patients with
osteonecrosis was 33% lower (P < 0.05) and the T½ of prednisolone
after i.v. administration was correspondingly longer than in patients
without necrosis (246 vs. 184 mm, P < 0.05). Thus, in spite of a
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considerable interindividual variation in the metabolism of prednisone,
a reduced metabolic clearance rate of prednisolone might be a contrib-
uting factor in the development of osteonecrosis after renal transplan-
tation.
Outcome of renal transplantation in patients treated with erythropoie-
tin. T. Linde, J. Wahlberg, B. WikstrOm, B.G. Danielson, and Depart-
ment of Internal Medicine and Transplant Surgery, University Hospi-
tal, Uppsala, Sweden. It has been suggested that a low hematocrit is
beneficial for early kidney graft function by protecting the transplanted
kidney from so-called reperfusion damage. Reperfusion injury is one
cause of acute tubular necrosis in transplanted kidneys. Due to renal
anemia, the great majority of patients waiting for kidney transplantation
until now have had a low hematocrit. The introduction of treatment
with recombinant human erythropoietin (rHuEPO) has, however,
raised the possibility of deleterious effects on early kidney graft
function, because of the resulting higher hematocrit. We have retro-
spectively examined the early function of 26 kidney grafts transplanted
to uremic patients with rHuEPO corrected anemia and compared with
an untreated randomized control group. (Pre-transplant Hb 105 22
glliter in the rHuEPO group versus 90 18 g/liter in the untreated
group, P < 0.01). No significant differences were seen in the rate of
immediate onset of graft function. The percentage functioning grafts
and serum levels of creatinine was equal during the initial three months
post-transplant. We conclude that the reversing of anemia by rHuEPO
in recipients of cadaver kidneys does not impair early graft function, at
least when the hemoglobin concentration is kept around 100—110 g/liter.
Loss of cortical bone mass after kidney transplantation. B. Linderga'rd,
B. Cederhoim, and J. Kurkus, Department of Nephrology, University
Hospital, Lund, Sweden. We have previously (Visby 1987) reported
that transplanted pts, evaluated with a single photon absorption (SPA)
technique, lose considerable amounts of mineral. This was true espe-
cially for elderly women who lost 1—5%/year. In 1985 we improved our
SPA technique so that now we can measure, not only the bone mineral
content (BMC), but also the outer and inner diameters of the tubular
bones of the forearms. Compared to age and sex matched controls, both
the outer and inner diameters of the bones were 4—9% greater despite
that the BMC was 8—14% less. One hundred and fifty transplanted pts
were followed for at least 2 years with our improved SPA technique.
Fifty of these have been analyzed to date. There was a significant
negative correlation between the increase of inner diameter (+ 1.9%!
year) and decrease of BMC and a positive correlation between loss of
BMC (—1.1%/year) and bone mass (—0.4%/year). There was also a
tendency to positive correlation between the increase in inner and outer
diameter (+0.4%/year). This increase in outer diameters is interesting,
as 25% of the pts who increased their inner diameters with at least
0.5%/year seemed to be able to also increase their outer diameter and
thereby maintain bone mass and BMC.
Quadruple versus triple immunosuppressive therapy in kidney trans-
plantation. P.K. Nielsen, K. Rasmussen, J.K. Kristensen, and K.
Ølgaard, Departments of Nephrology and Urology, Rigshospitalet,
University of Copenhagen, Denmark. Sixty-eight consecutive renal
transplant patients were treated with oral prednisone, azathioprine and
intravenous Minnesota-ALG (MALG) from transplantation until creat-
mine clearance was >10 mI/mm or for at least 3 days (mean 11 days).
Then MALG was substituted with cyclosporin A (CsA) and triple
therapy was continued. The course of these patients was compared to
a similar group of the 68 consecutive patients transplanted just before
MALG became available. These patients were treated with the same
triple therapy, but CsA treatment was started on the first postoperative
day. Six months after transplantation:
+ MALG - MALG P
Functioning grafts 85% 76% = 0.25
Acute rejection 32% 57% < 0.01
Time to rejection 26 days 14 days <0.05
Graft loss rejection 7% 18% < 0.01
Clinical infections 62 40 < 0.05
Time to graft function 11 days 11 days NS
Conclusion: Initial treatment with MALG after renal transplantation
resulted in significantly fewer episodes of acute rejection and less graft
loss due to acute rejection. The incidence of treated infections was
higher than during conventional triple therapy, and three grafts were
lost due to infection. Time to onset of graft function was the same in the
two groups. More grafts in the MALG group were functioning 6 months
after transplantation, but the difference between the groups was not
significant.
Parathyroid status after kidney transplantation (Tx). K.P. Nordal, E.
Dahi, J. Halse, andA. Flatmark, Medicine and Surgery Departments,
Rikshospitalet, Oslo, Norway. To study parathyroid status we did
biochemical tests and bone histomorphometry in 55 recipients (rec) 1
year after Tx. Results: 10 rec were hypercalcemic (HCa), and 45 were
normocalcernic (NCa) of whom 29 had increased PTH (Table).
Post-Tx HCa
N=l0
Post-Tx NCa
N=29 N=16
Creat mol/liter 130 39 207 73"' 139
Ca mmol/liter 2.77 0.07 2.46 0.09 2.49 0.10
PTH pg/liter 0.97 0.58c 1.05 046b 0.46 010b,c
ES% 93C 94b 5÷2b,c
Oc.S % 1.1 0.6 1.1 0.7 0.9 0.5
BFR un3/p,m2/year 33 18 43 20' 27 11"
a.bandc. p<001;dp<005
Abbreviations are: ES, eroded surface; BFR, bone formation rate;
Oc.S, osteoclast surface.
PTH correlated with creat, urinary cAMP and ES (r = 0.42—0.50; P <
0.01) in NCa rec but not in HCa. HCa rec had higher Ca and PTH also
at Tx than NCa rec. Conclusions: (I.) HPT is common 1 year after Tx.
(2.) Impaired renal function contributes to the sec HPT of NCa rec. (3.)
HCa occurs mainly in patients with excessive parathyroid activity at
Tx. (4.) The degree of HPT is appropriately reflected in the bone
biopsies.
Diabetic nephropathy and transplantation: Consequences of combined
pancreas and kidney transplantation compared with kidney transplanta-
tion only. G. Nordén, M. Olausson, L. Mjbrnstedt, G. Nyberg, Depart-
ment of Nephrology and Transplant Unit, Sahlgrenska sjukhuset,
Goteborg, Sweden. Detailed results of 12 combined pancreas and
kidney transplantations (Comb) were compared with those of two-
matched diabetic controls per patient; one living-donor kidney recipient
(LD) and one cadaveric-donor kidney recipient (CD) who, though
acceptable for pancreas, preferred kidney only. Mean follow-up was 22,
21 and 23 months in the Comb, CD and LD groups, respectively. There
was no mortality in the LD group but two CD and one Comb died, all
from cardiovascular disease. Two kidneys were lost in both the Comb
and the LD group compared to five in the CD group. Ten major vascular
events occurred, and three of them were lethal. The only LD case was
one below knee amputation, the other nine (three cardiovascular
deaths, two myocardial infarctions, one cerebral thrombosis, three
below knee amputations) were equally distributed in the Comb and CD
groups. Patients must be thoroughly informed about risks and options.
Immunomagnetic detection for anti-OKT3 antibodies: An easy, fast
and sensitive technique. J. V. Povlsen, Department of Clinical Immunol-
ogy, University Hospital of Aarhus, Aarhus N, Denmark. The purpose
of the present study was to develop a fast technique suitable for easy,
frequent and reliable detection of anti-OKT3 antibodies in single
samples. Tosyl-activated magnetizable Dynabeads (M-280), covalently
coated with OKT3, were used as solid phase. In the first step, coated
beads were incubated with diluted serum samples for 2 minutes. In the
second step, a polyclonal rabbit anti-human IgG, radiolabelled using the
iodogen method, was incubated for 10 minutes followed by determina-
tion of radioactivity associated with the beads. All steps in this
immunomagnetic assay (IMA) were performed at room temperature,
and each step was terminated by placing the test tube in a magnetic
particle concentrator for 1 minute before discarding the supernatant.
The IMA could be performed within 1 hour compared to 5 hours for a
conventional ELISA. For comparison, 3 dilutions of each of 25 serum
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samples from OKT3-treated allograft recipients were run in parallel in
both ELISA and IMA. Results, expressed as indices (mean ODor CPM
of the test sample divided with mean OD or CPM of a reference sample
from the same patient, drawn before the course of OKT3 treatment),
correlated significantly (P < 0.00001, Spearman test). However, 7
dilutions of the 75 tested (9%) came out positive (index 2) in IMA but
remained negative in ELISA, while no ELISA-positive, IMA-negative
samples were found, In conclusion, the present IMA, which seems
more sensitive than conventional ELISA, is easily adaptable to detec-
tion of other xenoantibodies, and may replace the ELISA in certain
situations where fast and frequent monitoring of single samples is
desirable, for example, when an acute (rebound) rejection episode is
suspected in a recipient previously treated with OKT3.
Pharmacokinetics of 2-mercaptopropionylglycine (2-MPG) in healthy
volunteers and cystinuric patients. MS. Carisson, T. Denneberg, B.-M.
Emanuelsson, B. Kâgedal, and S. Lindgren, Department of Nephrol-
ogy, Hospital Pharmacy and Clinical Chemistry, University Hospital,
Linkoping, Sweden. Cystinuria is an autosomal recessive disease where
cystine urolithiasis is often formed during the whole lifetime. Long-term
treatment is subsequently needed, Presently the drug of choice is
2-mercaptopropionylglycine (2-MPG), which forms a soluble mixed
disulphide with cystine. The pharmacokinetics of this drug is unknown
despite its clinical use for more than ten years. 2-MPG was given i.v.
and p.o. to 10 healthy subjects and p.o. to 4 cystinuric patients. Blood
and urine samples were collected for 48—72 hours for determination of
total and non-protein-bound 2-MPG. Results: Cmax was reached 3—6
hours after oral intake. Tl/2 was calculated to about 55 hours. A total of
75% was found in urine after i.v. given 2-MPG, while the corresponding
value after orally given 2-MPG was 34%. Most of the compound was
found within the first 6 hours. The bioavailability calculated from the
plasma curves was 66% (range 34—98%) and when calculated from the
urinary excretion it was 47% (range 27—71%). Conclusion: The long
half-life can probably be explained by slow release of tissue-bound
2-MPG. The rapid renal elimination suggests that at least two doses a
day should be given, with the greater part in the evening to prevent
stone formation.
Hypercalcemia in sarcoidosis. S. Cedgard, I. Ernest, H. Herlitz, and
B. Sjogren, Departments of Nephrology and Endocrinology, Sahigren-
ska Hospital, University of Goteborg, GOteborg, Sweden. Thirty-four
patients with sarcoidosis, hypercalcemia and renal impairment were
recorded in the western part of Sweden during the years 1965—90.
Eighteen of them were men and the mean age was 52 years (range
24—78). Mean serum creatinine (Sr) on admittance to hospital was 301
smol/liter (range 120—740). A GFR measurement (Cr-EDTA clearance)
was available in 21 patients (29 3 mI/mm). Mean values for serum
calcium and urinary calcium excretion were 3.06 0.14 mmol/liter and
13.7 1.1 mmol/24 hr, respectively. Our reference limits are 2.20—2.60
mmol/liter and 2—5 mmolI24 hr. Hypercalcemic symptoms occurred in
76% and nephrocalcinosis/nephrolithiasis in 38% of the patients. In 15
patients the diagnosis of sarcoidosis was verified by biopsy (lymph
node, lung, kidney or spleen) before and in three cases after treatment
had been instituted. Five patients presented with a clinical picture
which gave a strong suspicion of sarcoidosis and another 8 cases
responded promptly to prednisolone treatment. Thirty-one patients
were subjected to steroid treatment. During the first year S. normal-
ized in 21%, improved in 65% and was unchanged in 14%. Sixty percent
of the patients disclosed one or more relapses of hypercalcemia during
a 5 year period.
Acute renal failure necessitating dialysis treatment: A report on 419
consecutively treated patients from 1977 to 1988. H.E. Hansen, L. Frost,
and R.S. Pedersen, Department of Medicine and Nephrology C, Skejby
Hospital, University Hospital in Aarhus, Denmark. From January 1977
through December 1988, 419 patients had dialysis treatment for acute
renal failure (ARF). A total of 268 were males, 151 females, aged 0—81
years (median 52 years); 391 had anuria or oliguria, 28 were non-
oliguric; 175 had hemodialysis (HD), 214 peritoneal dialysis (PD) and 30
both HD and PD for 1—87 days (median 6.5 days). ARF was complicated
by circulatory failure in 207, respiratory failure in 246, thrombocytope-
nia in 87 and liver failure in 45 patients. A total of 53% were medical
cases, and 47% surgical cases with a mortality of 30% and 60%,
respectively, the overall mortality being 44%. One half of all deaths
occurred within 7 days and 90% within 21 days. The mode of treatment
did not affect patient survival but stepwise logistic regression analysis
disclosed etiology (medical/surgical) (P < 0.00001), number of organ
failures on admission (P < 0.00001), number of additional organ failures
after admission (P < 0.00001), age (P = 0.0009) and urine volume (P =
0.05) as independent significant risk factors. Year of patient admission
neither affected morbidity score nor patient survival significantly. The
prognosis in ARF is determined by the severity and progression of the
underlying disease process.
Nephropathia epidemica/hemorrhagic fever with renal syndrome. A.F.
JØrgensen, M. Strate, N. Foged, and H.K. Andersen, Department of
Nephrology Y, Odense University Hospital; and institute of Medical
Microbiology, University of Arhus, Denmark. Nephropathia epidemica
(NE) is characterized by fever, back and/or abdominal pain, acute renal
insufficiency and thrombocytopenia. Sixteen cases of NE were diag-
nosed on the island of Funen in 1990. Ages ranged from 22 to 57 years.
The renal insufficiency was preceded by a period with high fever,
headache and muscle pain. Severe abdominal symptoms sometimes
leading to surgery for "acute abdomen" were predominant, while
bleeding tendency hardly ever was noticed despite thrombocytopenia.
Three patients required dialysis. The recovery period was characterized
by severe polyuria. All patients recovered completely. The infectious
agent was the Puumula antigenic variant of Hantavirus diagnosed
serological by the presence of both 1gM and IgG antibodies. Almost all
cases could be referred to the same southeastern location of Funen,
where 7 similar cases were described over 30 years ago. The broad
clinical spectrum of the disease will be demonstrated by selected case
stories.
Modern principles in the treatment of cystine urolithiasis. A. Linde/I,
C. Ahistrand, T. Denneberg, J-O. Jeppsson, and H-G. Tiselius, De-
partments of Nephrology and Urology, University Hospital, Linkoping,
and Department of Clinical Chemistry, University Hospital, Ma/mo,
Sweden. During the last decade 2-mercaptopropinylglycine (2-MPG)
has appeared as the most promising pharmacological agent in the
prevention of cystine stone formation. Despite the improvement in
medical treatment of cystine urolithiasis with 2-MPG, some patients
still require surgery for the relief of urinary obstruction. Today extra-
corporeal shock wave lithotripsy (ESWL), instead of surgery, is the
established method of choice for removal of most renal stones. Its role
in the treatment of cystine urolithiasis has, however, been controversial
because of the difficulty to disintegrate cystine stones and the problem
of residual fragments. Patients and methods. Group 1: Thirty-one
patients with cystinuria on long-term treatment with 2-MPG were
followed 0.5—10 years (average 6.3 years). The urinary excretion of
cystine was measured regularly by means of ion-exchange chromatog-
raphy. Group 2: Eleven patients (12 kidneys) were treated with ESWL
combined with local chemolysis through percutaneous tubes. A solu-
tion of tromethamine alone, or in combination with a solution of
acetylcysteine in bicarbonate, was used as chemolytic agent. The stone
size ranged from 24 x 14 mm to a complete staghorn calculi. Results.
Group 1: By treatment with 2-MPG a urinary cystine concentration
below the stone forming level of 1200 mol/liter could be achieved in
most patients. The frequency of renal colic and/or urinary obstruction
was low. In 4 cases adverse effects caused withdrawal of the drug.
Group 2: Of the 12 ESWL-treated kidneys 7 became stone free. One
patient had a residual fragment in the ureter, another patient had
residual fragments in a lower calyx. Two stones were unaffected by the
treatment. In one patient there was a residual but untreated stone in a
calyx cyst. Conclusion: Treatment with 2-MPG is efficient in preventing
renal cystine stone formation with an acceptable level of side effects.
Regular monitoring of urinary cystine concentration during 2-MGP
treatment permits individualization of therapy within a wide dosage
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range (250—2500 mg124 hr). Cystine stones, even complete staghorns,
can be successfully treated in a minimally invasive way by ESWL and
local chemolysis. To solve the clinical problems in cystine urolithiasis a
strategy which combines ESWL and long-term treatment with 2-MPG is
recommended.
Anti-tubular basement membrane disease. B. Lindqvist, L. Lundberg,
V. Kozma, and J. Wieslander, Department of Medicine, University
Hospital, Umea', and BioCarb Technology AB, Lund, Sweden. Anti-
tubular basement membrane antibodies were determined by ELISA in
patients with renal diseases. The determination in serum was performed
by Biocarb AB, Lund, and was based on a 58 kD bovine tubular
basement membrane antigen. Sera from 73 patients with different forms
of interstitial nephritis were investigated. Fifteen patients (10 women
and 5 men) had a titer above the normal, in comparison with a reference
group of blood donors. The patients will be presented in more details.
Sera from 34 patients with pyelonephritis (confirmed by urography)
were investigated. One patient had a positive titer. We have found 12
patients with antibodies against the glomerular basement membrane
who also had antibodies against the tubular basement membrane
antigen. Of these 12 patients 4 had glomerulonephritis, 3 pyelonephritis,
2 renal artery stenosis, 1 Goodpasture's disease, I Wegener's granulo-
matosis and 1 vasculitis. The specificity of the test to diseases in the
renal medulla is not clear. Conclusion: The test supports the opinion
that damage in the renal medulla can be caused by an auto-immune
process. The cause and prognosis of this anti-tubular basement mem-
brane disease is not known.
Early prediction of prognosis in IgA nephropathy by measurement of
51Cr-EDTA clearance. S. Rekola, A. Bergstrand, and H. Bucht, Karo-
linska Institute, Department of Nephrology, Huddinge Hospital, Stock-
holm, Sweden. In 153 patients with IgA nephropathy (IgAN) GFR was
measured with repeated clearances of 51Cr-EDTA (mI/mm/I .73 in2).
The annual change of GFR was calculated from the regression line of
5!CrEDTA clearances. A total of 50.3% of the patients had a loss of
more than 1.1 mI/mm/year. Of 93 patients with initially normal GFR
32% will have a subnormal GFR within 5 years, and 25% will develop
end-stage renal failure within 25 years, calculated with renal survival
statistics. In 38 patients with six or more clearance measurements the
predictive value of the first four determinations was calculated. Of 26
with an annual decrease of more than 1.1 mI/mm, 13 developed
subnormal GFR during follow-up, but only one of 12 with an annual
decrease of less than 1.1 mI/mm (fig.) (P < 0.05). Repeated early
determinations of GFR are of predictive value in IgAN.
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Proteinuria in IgA nephropathy in relation to the blood pressure and
treatment of hypertension. S. Re/cola, A. Bergstrand, and H. Bucht,
Karolinska Institute, Department of Nephrology, Huddinge Hospital,
Stockholm, Sweden. High urinary output of protein is a well known
predictor of a poor prognosis in IgA nephropathy. An increase in
proteinuria is regarded as a sign of a progressive disease, and a decrease
of protemnuria could indicate a more benign course. One hundred and
eighty patients have been followed regularly with 24-hour urinary
protein excretion and clearance of 51Cr-EDTA among other parame-
ters. Results: The mean proteinuria (g124 hr) was calculated for all
patients, during periods with no treatment, and during treatment with
an ACE inhibitor (enalapril) or beta blocking agents (different) in
hypertensive subjects.
N
Proteinuria
PFirst Follow-up
All 180 1.17 0.98
Untreated 134 1.02 1.03
Beta blockers 36 1.71 1.75
ACE inhibitors 24 2.08 1.41 <0.05
Changes in selectivity index were also calculated but permitted no
conclusions. There was a weak correlation between a decrease in GFR
and an increase in proteinuria. Conclusion: We have showed earlier that
the deterioration of GFR is faster during treatment with beta blocking
agents than with an ACE inhibitor. Our present results with a decrease
in proteinuria confirm that ACE inhibitors should be preferred in
treatment of hypertension in IgA nephropathy.
Reliability of glomerular filtration rate measurements. J. Stentoft,
BA. Jacobsen, EM. Nielsen, H.H. Rasmussen, and K. Terkildsen,
Department of Medicine C; Department of Clinical Physiology, Au/-
borg Hospital, Denmark. This study tested the reliability of 24-hour
creatinine clearance (Cl0), overnight creatinine clearance (CIN), and
creatinine clearance estimated a.m. Kampmann (OK) as measurements
of glomerular filtration rate. Seventy-four hospitalized adult patients
representing a wide range of renal function were selected. GFR =
51Cr-EDTA clearance was used as gold standard. Endogenous creati-
nine clearance was used duplicate measurements of Cl0, CIN, and CIK.
Weighted regression analysis was used to relate mean of Cl0, CIN, and
CIK, respectively, to GFR. Based on the regression equation Cl0, CIN,
and CIK, were transformed to their respective estimates of GFR
(GFRest). The 95% prediction intervals, that is, the interval in which
the actually measured GFR will be found, were calculated. There was
no clinically significant difference between Cl0, CIN, and CIK as regards
the prediction of GFR. The prediction of GFR from GFRest was
relatively more unreliable in the low range. Examples:
N GFRest
95%
pred. mt. GFRest
95%
pred. mt.
Cl0 69 25 14—46 100 74—136
CIN 61 25 12—51 100 69—144
C1K 72 25 l3—49 100 71—140
Conclusion: The estimates of GFR provided by 24-hour creatinine
clearance, overnight creatinine clearance and creatinine clearance
estimated a.m. Kampmann are almost equal. However, the estimates
are imprecise, especially in the low range.
Acute etracapillary necrotic glomerulonephritis: Prognosis as affected
by plasmapheresis and other therapeutic measures. U. Strdmbom, H.
Thysell, C. Svalander, and G. Westberg, Department of Nephrology,
University Hospital of Lund, Departments of Nephrology and Pathol-
ogy, Sahlgrenska Hospital, Goteborg, Sweden. In patients with acute
necrotic glomerulonephritis admitted to the above university clinics
1978—1989 we are monitoring the outcome of treatments in relation to
inter a/ia histopathological, imrnunohistochemical and biochemical8 0 findings. Patients with specific BM antibodies, with SLE, with hy-
dralazin-induced nephntis and with predominant exacerbation of
chronic disease were not included. Of 62 patients with crescentic
nephntis so far studied, 33 underwent plasmapheresis and 29 did not.
These groups did not differ as to age, clinical diagnosis or pharmaco-
logical immunosuppression used. Most patients are now followed for
two years, some for five years. The serum creatinine level in the two
groups is virtually identical up to five years after treatment. The
mortality rate in each group is about 10% to date. The pretreatment
mean creatinine level in the plasmapheresis-treated group was 613
mmol/liter, vs. 395 in the other group. This difference was not present
from 1 month after initiation of treatment. Excluding all patients
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diseased within 1 year and also those with initial creatinine levels below
350, similar relations between creatinine levels of plasmapheresis-
treated and controls appeared to prevail. Interestingly, no correlation
was found between the initial and 1 year creatinine values in the
plasmapheresis-treated group, respectively, as opposed to controls,
suggesting a possible beneficial effect of plasmapheresis. So far, how-
ever, the results fail to support a long-term health gain of this treatment.
Urinary protein excretion (UPE) and glomerular filtration rate (GFR)
in relation to renal morphological changes in childhood and adult IgA
nephropathy (IgAN). U. Widstam-Attorps, U. Berg, and S-O. Bohman,
Departments of Renal Medicine, Paediatrics and Pathology, Karolin-
ska Institute, Huddinge Hospital, Huddinge, Sweden. At the time of
kidney biopsy GFR and UPE were studied in 24 children and 54 adult
patients with IgAN, Glomerular, tubulointerstitial and vascular biopsy
changes were classified on a five degree scale. Glomeruli with global!
segmental sclerosis and crescents were assessed. GFR was measured
by inulin clearance in the children and by 51Cr-EDTA clearance in the
adults. For tJPE albumin (alb), IgG and creatinine were analyzed, and
excretion rates (UV) were calculated. A total of 70% adult IgA patients
had overt albuminuria vs. 21% children. In both children and adults
GFR was lowered in the albuminuric patients, but also the microalbu-
minurics had reduced mean GFR. UIgGV increased with rising albumi-
nuria. The children had less prominent morphological lesions than the
adults. Still, 25% of the children had reduced GFR. Of the adults 33%
had reduced GFR, 6% uremia. In both groups patients with more
advanced mesangial/interstitial/sclerotic changes had lower GFR than
those with no or slight damage. No arteriolosclerosis was found in the
children, but more than half of them had glomerular sclerosis, and
highly significant correlations were found between segmental sclerosis
and UbV (r = 0.80) and U1g0V (r = 0.87). In the adults these
correlations were less prominent but significant. In summary, childhood
IgAN does not seem as harmless as previously reported. Rising U1g0V
seems to indicate both reduced GFR and increasing segmental glomer-
ulosclerosis and may be predictive of progressive disease.
Influence of hypo- and hyperglucocorticoidism on the metabolism of
aldosterone in the isolated perfused rat liver. M. Egfjord, H. Daugaard,
and K. Ølgaard, Medical Department P, Division of Nephrology,
Rigshospitalet, University of Copenhagen, Denmark. The effect of
adrenalectomy and dexamethasone (0.3 mg kg/day) on the metabolism
of 4-'4C-d-aldosterone (at 10 M) was studied in the isolated perfused rat
liver. Aldosterone was measured by RIA. Radiometabolites in perfus-
ate and bile were analyzed by HPLC. Adrenalectomy did not affect
hepatic metabolism of aldosterone. Dexamethasone treatment resulted
in 17% lower body weight (P < 0.00 1) and 11% lower liver wet weight
(P < 0.05), when compared to normal rats. The clearance of aldoste-
rone was 19% lower (P < 0.05) in livers of dexamethasone rats than in
livers of normal rats. In livers of dexamethasone treated rats, at 5
minutes perfusate 4-'4C-aldosterone metabolites were lower than in
livers of normal rats (P < 0.05). The pattern of hepatic polar aldoste-
rone metabolites in perfusate and in bile was similar in all groups,
except of higher amounts of conjugated tetrahydroaldosterone excreted
in bile of dexamethasone treated rats. Thus, high-dose dexamethasone
therapy may lead to a lower total capacity of the hepatic clearance of
aldosterone, which may contribute to elevated plasma aldosterone level
in situations with stimulated adrenal secretion of aldosterone.
Non-invasive ultrasound assessment of significant renal artery stenosis
by use of the gosling pulsatility index (P1). G. Jensen, M. Bardelli, R.
Volkmann, and M. Aurell, Departments of Nephrology and Clinical
Physiology, Sahlgren's Hospital, University of Goteborg, Sweden.
Despite the difficulties in assessing renal artery stenosis (RAS) directly
with ultrasound we aimed to develop a valid Doppler test for RAS,
since kidney blood flow velocities can easily be detected with the
Echo-Color-Doppler in the interlobar arteries (IA). Twenty healthy
volunteers were investigated with ultrasound only, 52 hypertensive
patients were investigated with ultrasound, and 45 of these with
angiographic signs of RAS underwent bilateral renal vein catheteriza-
tion. p-blockers and ACE inhibitors were omitted prior to the study.
Significant RAS was defined by angiographic stenosis of >50% com-
bined with positive renin output and decrease in filtration fraction after
ACE inhibition. In both kidneys renal blood flow velocities of IA were
measured with pulsed Doppler technique, and P1 of flow velocity
spectra was calculated. There were no drop-outs for technical or
anatomical reasons. Results: P1 in 40 healthy kidneys was 0.96 01.2
(mean SD) and the mean difference between P1 of both kidneys was
0.06 0.03. In 18 hypertensive (11 renin negative) patients, P1 was 1.21
0.30 and a side difference was only found in two subjects. Twenty-
one renin positive patients with unilateral RAS (URAS) had a signifi-
cantly lower P1 in the stenotic kidney as compared with the non-
stenotic kidney: 0.94 0.23 versus 1.29 0.30 (P < 0.0001). Side
differences >0.12 were found in 19 patients with a mean value of 0.35
0.24. Five patients with occlusive RAS (ORAS) showed no Doppler
flow signal. Eight patients with angiographic bilateral RAS (BRAS) P1
was 0.85 0.13 in both kidneys. Only in one patient a significant side
difference of P1 was found. Conclusion: The absence of parenchymal
Doppler-signals indicate ORAS. A side difference of P1 > 0.12 and/or an
absolute value of P1 <0.94 predicts URAS, while P1 < 1.09 bilaterally
in hypertensives indicates BRAS. A correct diagnosis was achieved
with a sensitivity of 96% and a specificity of 72%.
Prostaglandin production and immunoregulatory effects of Captopril.
S.A. Johnsen, 1.-B. Persson, and M. Aurell, Department of Nephrol-
ogy, University of GOteborg, Goteborg, Sweden. The Immunoregula-
tory effect of Captopril (C) on OKT3 stimulated lymphocytes was
investigated ex vivo. C was given to 9 healthy volunteers. Blood
samples were drawn before and 2 hours after drug intake. Lymphocyte
proliferation was tested with various concentrations of plasma in the
cultures with and without addition of Indomethacin. We found a 40%
suppression of proliferation (P < 0.01) in cultures where lymphocytes
from blood drawn after C were cultured in 30% plasma drawn before C.
This suppression was inhibited by indomethacin. The concentration of
exogenous PGE2 that had to be added to the cultures in order to
counteract the effect of indomethacin was about 5 x l0 M. Plasma
drawn after C had no suppressive effect, in combination with indometh-
acm at some concentrations a stimulatory effect was found. It is
concluded that C stimulates prostaglandin production in the cultures,
and that the immunoregulatory effects of C involve plasma-dependent
stimulatory and suppressive mechanisms.
Therapy with an organic marine hydrocolloid (OMH)—Effects on
enteric hyperoxaluria and intractable diarrhea. M. Lindsjö, U. Back-
man, S. Ejerbiad, B. Fellström, B. Wiktrom, B.G. Danielson, Depart-
ments of Medicine and Surgery, University Hospital, Uppsala, Swe-
den. It was recently shown that OMH had the capacity to bind oxalate
both in vitro and in viva in patients with enteric hyperoxaluria following
jejunoileal bypass or Crohn's disease with bowel resection. All of these
patients spontaneously reported improvements of intractable diarrheas.
The alms of the present study was to evaluate the effect of OMH on
frequency and consistency of stools in patients with ileal resection of
different length and the effect on the 24-hour urinary oxalate excretion.
In the present study, 2 patients with jejunoileal bypass and 18 patients
with Crohn's disease and ileal resection with hemicolectomy (14),
subtotal colectomy (2) and resection of the coecum (2) were included.
OMHs are polymers of high molecular weight extracted from plants and
seaweeds. This OMH (Ox-Absorb®, Vitaline, Oregon, USA) is spe-
cially processed and charged with calcium and zinc. The patients were
given OMH I g, 2—3 capsules t.i.d. with the meals. Frequency and
consistency of the stools were reported in a protocol during one week
without treatment and after one and 6 months on therapy. Urinary
collections were made over 24-hour periods in plastic bottles containing
hydrochloric acid. Urinary oxalate was analyzed by using Sigma kit 590
(ref range 55—400 mol/24 h). Other serum and urinary constituents
were determined by automated techniques as part of the routine clinical
chemistry. The frequency of stools was significantly reduced (P <
0.001) from 34 4 to 26 3 (mean SEM) after one month and to 21
3 after 6 months (P < 0.05). The 24-hour urinary oxalate excretion
was significantly reduced after one (P < 0.01) and 6 months (P < 0.01).
There were no significant differences between other serum and urinary
constituents. Summary. OMH treatment causes a significant reduction
of bowel movements. The 24-hour urinary oxalate excretion is reduced,
which can be anticipated to reduce the frequency of renal stone
formation. Serum levels of electrolytes, iron, folate, vitamin B 12, zinc
and PTH are unchanged, like the urinary electrolyte excretions. Eight
of the patients are stone formers, and these patients have on average the
most extensive ileal resection. The patient compliance to the OMH
treatment is very good.
Abstracts
Use of electronic data processing for clinical, administrative and
scientific purposes in a renal unit. H. LØkkegaard and T. Andersen,
Medical Department B and Department of Medical Data Processing,
County Hospital in Herlev, Herlev, Denmark. Patients in active treat-
ment of ESRD are characterized by accumulation of considerable
amounts of clinical and laboratory data. The electronic data processing
technique is useful to help the staff with relevant data information in
relation to therapeutic, administrative and scientific purposes. How-
ever, introduction of this technique raises a number of technical as well
as organizing problems, and so far this has limited its use in many
centers. We have five year experiences with our electronic data
processing designed for dialysis and transplant recipients. A compiled
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dBASE version forms the basis for input of clinical data from PCs and
automatic transfer of laboratory data. Output is available on the PCs.
Data are secured according to the Danish law of registration. Individual
output can be worked out by users according to requirements and
stored for further use. Output can be shown on the display monitor,
sent to a printer or stored as ASCII files and transferred to statistical
programs. Programs for transfer of data to the Danish Renal Registry
and the EDTA registry have been developed. It is the purpose with this
presentation to show our current results, and to discuss further appli-
cations in relation to other electronic data processing systems and
registers involved in patients with chronic renal failure.
